

CITATION REPORT

List of articles citing

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

DOI: 10.1016/s1470-2045(11)70393-x
Lancet Oncology, The, 2012, 13, 239-46.

Source: <https://exaly.com/paper-pdf/53168194/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2151	Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. 2009 , 6, 260-70		43
2150	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. 2012 , 19, S73-85		9
2149	Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. 2012 , 23 Suppl 10, x193-6		12
2148	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. 2012 , 19, S52-8		96
2147	Going beyond EGFR. 2012 , 23 Suppl 10, x197-203		8
2146	Personalized targeted therapy for lung cancer. 2012 , 13, 11471-96		45
2145	Human correlates of provocative questions in pancreatic pathology. 2012 , 19, 351-62		23
2144	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii56-64		342
2143	Worldwide overview of the current status of lung cancer diagnosis and treatment. 2012 , 136, 1478-81		47
2142	Gastrointestinal stromal tumors. 2012 , 6-26		
2141	The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. 2012 , 19, 3337-52		30
2140	Management of advanced lung cancer in resource-constrained settings: a perspective from India. 2012 , 12, 1479-95		29
2139	Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. 2012 , 35, 509-13		11
2138	Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. 2012 , 30, 3417-20		48
2137	Pleural mesothelioma. 2012 , 114-135		
2136	Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. 2012 , 17, 863-70		81
2135	Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. 2012 , 12, 1299-312		3

2134 [Therapeutic standards and perspectives for stage IV non-small cell lung cancer]. **2012**, 35 Suppl 3, 10-3

2133 Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer. **2012**, 35, 600-3 12

2132 Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. **2012**, 7, 1807-1814 454

2131 Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. **2012**, 7, 1722-7 81

2130 EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer?. **2012**, 7, 1739-1741 3

2129 Applying biomarker testing to clinical practice in lung cancer. **2012**, 1, 145-154

2128 Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. **2012**, 2, 895-907 1

2127 Lung adenocarcinoma. **2012**, 136-165

2126 Metastatic melanoma. **2012**, 28-49

2125 Gastric cancer. **2012**, 90-112

2124 Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. **2012**, 7, 1815-1822 128

2123 EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. **2012**, 7, e19-20 21

2122 First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors. **2012**, 1, 201-217

2121 Triple-negative breast cancer. **2012**, 74-88 1

2120 Molecular-Based Decision Making for Personalized Cancer Management. **2012**,

2119 Ask the Experts: EGFR mutation and non-small-cell lung cancer: EGFR test, cost and quality of life. **2012**, 1, 169-172

2118 Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. **2012**, 7, 1830-1844 17

2117 Circulating tumor cells in lung cancer. **2012**, 1, 105-112 1

2116	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). 2012 , 7, 1490-502		65
2115	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012 , 17, 1351-75		175
2114	Non-small cell lung cancer: One size doesn't fit all. 2012 , 8, 211-2		
2113	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. 2012 , 2, 934-47		212
2112	Lung cancer genotype-based therapy and predictive biomarkers: present and future. 2012 , 136, 1482-91		33
2111	Clinical and economic review of erlotinib in non-small-cell lung cancer. 2012 , 12, 411-23		8
2110	Beyond first-line NSCLC therapy: chemotherapy or erlotinib?. <i>Lancet Oncology, The</i> , 2012 , 13, 225-7	21.7	11
2109	Optimising therapy for EGFR-addicted NSCLC: just the start. <i>Lancet Oncology, The</i> , 2012 , 13, 216-7	21.7	2
2108	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 539-48	21.7	331
2107	A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. <i>Lancet Oncology, The</i> , 2012 , 13, 442-3	21.7	11
2106	La maladie oligométastatique dans le cancer bronchique non ^petites cellules. 2012 , 4, 639-644		
2105	Prise en charge thérapeutique des cancers bronchiques non ^petites cellules métastatiques mutés pour l'EGFR. 2012 , 4, 583-598		0
2104	Disparities in subgroup populations enrolled in lung cancer trials. 2012 , 6, 163-72		
2103	The role of biomarkers in cancer clinical trials. 2012 , 28, 116-21		6
2102	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. 2012 , 30, 3077-83		154
2101	Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. 2012 , 30, 3330-6		38
2100	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. 2012 , 30, 3002-11		193
2099	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. 2012 , 5, 62		25

2098	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. 2012 , 6, 337-45		40
2097	NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2012 , 13, 764-5	21.7	5
2096	EGFR mutations in circulating tumour DNA. <i>Lancet Oncology, The</i> , 2012 , 13, 971-3	21.7	25
2095	First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1161-70	21.7	142
2094	Who should receive EGFR tyrosine-kinase inhibitors?. <i>Lancet Oncology, The</i> , 2012 , 13, 1074-6	21.7	2
2093	Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma. 2012 , 77, 469-72		25
2092	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). 2012 , 78, 239-44		26
2091	Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. 2012 , 19, S33-44		38
2090	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. 2012 , 31, 807-14		110
2089	Les biomarqueurs ^rechercher en 2012 et dans le futur proche dans les cancers bronchiques non ^ petites cellules (CBNPC). 2012 , 4, 578-582		
2088	Lungenkrebs: Operation, Strahlentherapie und systemische Therapie. 2012 , 7, 133-139		
2087	Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. 2012 , 72 Suppl 1, 3-10		5
2086	Recurrent oral cancer: current and emerging therapeutic approaches. 2012 , 3, 149		74
2085	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. 2012 , 2, 77-92		2
2084	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Inhibitors and Overcoming Strategies in Lung Cancer. 2012 , 11, 59		2
2083	MET targeted therapy for lung cancer: clinical development and future directions. 2012 , 3, 53-67		4
2082	Crizotinib in the treatment of non-small-cell lung carcinoma. 2012 , 16, 480-4		3
2081	Cancer stem cells, microRNAs, and therapeutic strategies including natural products. 2012 , 31, 733-51		50

2080	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. 2012 , 13, 789-802		31
2079	Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer. 2012 , 138, 1385-94		2
2078	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. 2013 , 119, 3761-8		37
2077	EGFR mutations in malignant pleural effusions from lung cancer. 2013 , 2, 79-87		8
2076	Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. 2013 , 2, 17-21		1
2075	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. 2013 , 119, 3043-51		18
2074	Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. 2013 , 115, 95-101		23
2073	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. 2013 , 9, 991-1003		6
2072	Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations. 2013 , 17, 57-62		4
2071	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. 2013 , 13, 354		35
2070	Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. 2013 , 13, 210		31
2069	Fool's gold, lost treasures, and the randomized clinical trial. 2013 , 13, 193		36
2068	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology, The</i> , 2013 , 14, 981-8	21.7	402
2067	Update in lung cancer and mesothelioma 2012. 2013 , 188, 157-66		23
2066	Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. 2013 , 191, 491-9		34
2065	Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy. 2013 , 191, 271-80		3
2064	Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?. 2013 , 15, 959-64		2
2063	Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. 2013 , 462, 409-19		25

2062	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. 2013 , 48, 544-8	51
2061	Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. 2013 , 19, 833-8	22
2060	Lungenkarzinom und Pleuramesotheliom. 2013 , 10, 23-30	
2059	Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. 2013 , 31, 891-9	7
2058	Management of non-small-cell lung cancer: recent developments. 2013 , 382, 709-19	563
2057	Genetics and biomarkers in personalisation of lung cancer treatment. 2013 , 382, 720-31	223
2056	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). 2013 , 8, 27-33	82
2055	Clinical meta-analyses of targeted therapies in adenocarcinoma. 2013 , 8, 35-45	3
2054	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. 2013 , 8, 55-67	66
2053	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. 2013 , 71, 859-65	7
2052	[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing]. 2013 , 34, 310-7	5
2051	Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. 2013 , 73, 517-32	5
2050	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. 2013 , 73, 357-69	12
2049	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. 2013 , 109, 1821-8	92
2048	Clinical perspective of afatinib in non-small cell lung cancer. 2013 , 81, 155-61	43
2047	EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?. <i>Lancet Oncology, The</i> , 2013 , 14, 916-7	21.7 11
2046	Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. 2013 , 119, 2754-64	91
2045	[Supportive, palliative care in lung cancer]. 2013 , 30, 137-41	0

2044	Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. 2013 , 14, 224-9	10
2043	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. 2013 , 37, 110-44	40
2042	Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months. 2013 , 10, 10-2	0
2041	A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. 2013 , 82, 299-304	26
2040	Targeted therapy and new anticancer drugs in advanced disease. 2013 , 23, 411-9	7
2039	A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. 2013 , 82, 276-81	28
2038	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. 2013 , 80, 120-30	40
2037	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. 2013 , 39, 839-50	84
2036	Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine. 2013 , 73, 4185-9	3
2035	The quest to overcome resistance to EGFR-targeted therapies in cancer. 2013 , 19, 1389-400	684
2034	CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. 2013 , 80, 242-8	53
2033	[Smoking cessation therapy in thoracic oncology]. 2013 , 30, 696-705	0
2032	Nonsmall cell lung cancer. 2013 , 22, 33-6	17
2031	Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?. 2013 , 80, 352-3	
2030	[Characterization of principal predictive biomarkers of targeted therapies in thoracic cancer]. 2013 , 71, 369-75	
2029	Câncer de pulmão no microcâncer. 2013 , 11, 1429-1440	
2028	Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. 2013 , 82, 373-4	64
2027	Targeted therapy for NSCLC with driver mutations. 2013 , 13, 1401-12	33

2026	Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. 2013 , 49, 3111-21	58
2025	Adjuvant treatment in resected non-small cell lung cancer: current and future issues. 2013 , 88, 375-86	9
2024	Crizotinib in the treatment of non--small-cell lung cancer. 2013 , 14, 473-80	32
2023	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. 2013 , 13, 1207-18	10
2022	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 2013 , 8, 1381-97	6
2021	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. 2013 , 24, 2080-7	92
2020	A genomics-based classification of human lung tumors. 2013 , 5, 209ra153	302
2019	Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. 2013 , 36, 439-48	33
2018	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. 2013 , 15, 977-84	17
2017	Clinical analysis and interpretation of cancer genome data. 2013 , 31, 1825-33	107
2016	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. 2013 , 66, 839-46	23
2015	Is EGF receptor tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?. 2013 , 2, 441-443	
2014	Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. 2013 , 14, 609-26	14
2013	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. 2013 , 88, 477-93	53
2012	HER2 and lung cancer. 2013 , 13, 1219-28	50
2011	KRAS mutations in lung cancer. 2013 , 14, 205-14	149
2010	Genomische Analytik kleinzelliger Lungenkarzinome – neue Möglichkeiten in der Therapie?. 2013 , 19, 958-961	
2009	Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung. 2013 , 14, 568-79	5

2008	Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use. 2013 , 14, 595-609	11
2007	Detecting EGFR alterations in clinical specimens-pitfalls and necessities. 2013 , 463, 755-64	4
2006	Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. 2013 , 72, 1299-1304	10
2005	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology, The</i> , 2013 , 14, 953-61	21.7 307
2004	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. 2013 ,	2
2003	Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. 2013 , 10, 551-2	51
2002	Epidermal growth factor receptor: pathway, therapies, and pipeline. 2013 , 35, 1282-303	66
2001	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?. 2013 , 31, 1081-8	89
2000	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. 2013 , 9, 1037-51	9
1999	The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. 2013 , 62, 609-16	13
1998	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. 2013 , 31, 1070-80	362
1997	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013 , 31, 3327-34	2262
1996	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. 2013 , 31, 3335-41	257
1995	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. 2013 , 31, 3342-50	222
1994	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. 2013 , 66, 79-89	228
1993	Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. 2013 , 49, 1216-25	79
1992	Impact of genetic markers on treatment of non-small cell lung cancer. 2013 , 779, 145-64	6
1991	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. 2013 , 24, 59-66	82

1990	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013 , 31, 992-1001		365
1989	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. 2013 , 31, 1039-49		357
1988	ALK in lung cancer: past, present, and future. 2013 , 31, 1105-11		319
1987	New targetable oncogenes in non-small-cell lung cancer. 2013 , 31, 1097-104		249
1986	New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 2013 , 31, 1029-38		61
1985	Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. 2013 , 11, 307-9		1
1984	Molecular profile of lung cancer in never smokers. 2013 , 11, 248-53		19
1983	A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). 2013 , 82, 109-14		66
1982	Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report. 2013 , 9, 8-10		11
1981	Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. 2013 , 81, 455-461		33
1980	Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. 2013 , 206, 73-80		35
1979	Mutation de l'EGFR, de l'étude du gène à la pratique clinique : exemplarité ou exception ?. 2013 , 5, 519-537		
1978	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology, The</i> , 2013 , 14, 619-26	21.7	141
1977	Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples. 2013 , 6, 504-10		6
1976	The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. 2013 , 14, 311-21		10
1975	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. 2013 , 82, 231-7		58
1974	Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma. 2013 , 80, 289-92		16
1973	Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis. 2013 , 14, 333-41		9

1972 Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques. **2013**, 5, 427-435

1971 Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. **2013**, 31, 3987-96 260

1970 Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. **2013**, 81, 328-336 45

1969 Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?. **2013**, 81, 347-353 69

1968 Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. **2013**, 80, 191-6 11

1967 Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. **2013**, 79, 283-8 58

1966 Incidence and consequences of bone metastases in lung cancer patients. **2013**, 2, 22-9 54

1965 [Biological diagnosis of resistance to erlotinib in a malignant pleural effusion]. **2013**, 30, 572-5 1

1964 EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. **2013**, 81, 440-444 33

1963 [About new treatments in thoracic oncology]. **2013**, 69, 63-4

1962 The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. **2013**, 30, 298-312 10

1961 Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer. **2013**, 14, 719-25 18

1960 [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration]. **2013**, 30, 351-6 9

1959 Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. **2013**, 79, 167-72 21

1958 FASTACT-2: but don't act too fast. *Lancet Oncology, The*, **2013**, 14, 684-5 21.7 5

1957 [Lung cancer in nonsmoker: a separate entity]. **2013**, 30, 527-8

1956 EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. **2013**, 82, 38-43 24

1955 Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer. **2013**, 80, 344-6 3

1954	Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. 2013 , 30, 349		26
1953	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 38-47	21.7	536
1952	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. 2013 , 73, 834-43		153
1951	EGFR inhibition in non-small cell lung cancer: current evidence and future directions. 2013 , 1, 2		25
1950	Surgery for NSCLC in the era of personalized medicine. 2013 , 10, 235-44		75
1949	Mediating resistance in oncogene-driven cancers. 2013 , 368, 1551-2		17
1948	Hedgehog signaling pathway and cancer therapeutics: progress to date. 2013 , 73, 613-23		54
1947	Novel therapeutic targets in non-small cell lung cancer. 2013 , 13, 394-401		59
1946	Identification of driver mutations in lung cancer: first step in personalized cancer. 2013 , 8, 3-14		20
1945	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. 2013 , 93, 252-9		177
1944	Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology. 2013 , Chapter 14, Unit 14.26		15
1943	Erlotinib in the first-line treatment of non-small-cell lung cancer. 2013 , 13, 523-33		15
1942	EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. 2013 , 80, 306-12		38
1941	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. 2013 , 39, 489-97		25
1940	Companion biomarkers: paving the pathway to personalized treatment for cancer. 2013 , 59, 1447-56		37
1939	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013 , 368, 2385-94		2594
1938	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. <i>Lancet Oncology, The</i> , 2013 , 14, 777-86	21.7	237
1937	Targeted therapy for non-small-cell lung cancer: past, present and future. 2013 , 13, 745-58		68

1936	Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes. 2013 , 143, 597-600	2
1935	The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. 2013 , 3, 369-383	2
1934	EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. 2013 , 15, 396-404	23
1933	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 15, 415-53	340
1932	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. 2013 , 79, 33-9	122
1931	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 137, 828-60	365
1930	Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation. 2013 , 13, 529	10
1929	Personalizing health care: feasibility and future implications. 2013 , 11, 179	63
1928	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. 2013 , 82, 31-7	42
1927	Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. 2013 , 31, 4105-14	391
1926	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 2013 , 14, 597-608	6
1925	Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. 2013 , 84, 255-64	9
1924	Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. 2013 , 31, 1858-65	103
1923	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. 2013 , 139, 1691-700	25
1922	Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. 2013 , 19, 821-834	
1921	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 , 8, 823-59	632
1920	Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). 2013 , 8, 1409-16	20
1919	Personalized Management of Lung Cancer. 2013 ,	

1918	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. 2013 , 19, 818-832	23
1917	Clinical characteristics of 274 non-small cell lung cancer patients in China. 2013 , 36, 248-54	12
1916	Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report. 2013 , 6, 189-96	4
1915	The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. 2013 , 19, 2629-36	73
1914	Advances in personalized therapy for lung cancer. 2013 , 7, 475-85	8
1913	Treatment of lung cancer: will financial issues become a criterion of choice?. 2013 , 13, 273-5	3
1912	[Gender-specific difference in lung cancer]. 2013 , 67, 270-9	2
1911	RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. 2013 , 201, W64-71	31
1910	[Brain metastases of non small cell lung cancers: systemic treatments]. 2013 , 100, 95-8	2
1909	Diarrhea associated with afatinib: an oral ErbB family blocker. 2013 , 13, 729-36	73
1908	[Targeted treatment of advanced lung cancer]. 2013 , 138, 2034-6	
1907	Geschlechtsspezifische Unterschiede beim Lungenkarzinom. 2013 , 34, 459-468	
1906	Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungenkarzinom (NSCLC) â aktueller Stand und Entwicklungen. 2013 , 34, 469-476	
1905	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. 2013 , 22, 565-76	18
1904	Afatinib in advanced non-small-cell lung cancer. 2013 , 2, 493-504	
1903	Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. 2013 , 137, 481-91	40
1902	[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments]. 2013 , 67, 494-501	1
1901	Targeted therapy for non-small cell lung cancer. 2013 , 188, 907-12	19

1900	How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?. 2013 , 9, 825-9	2
1899	Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. 2013 , 19, 927-939	27
1898	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. 2013 , 9, 327-45	8
1897	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. 2013 , 19, 4532-40	238
1896	Epidemiology of lung cancer. 2013 , 30, 93-8	190
1895	Personalizing therapy in advanced non-small cell lung cancer. 2013 , 34, 822-36	14
1894	Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. 2013 , 8, 773-8	18
1893	Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer. 2013 , 23, 1-6	0
1892	Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 2013 , 137, 668-84	287
1891	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. 2013 , 1, 575-581	37
1890	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. 2013 , 12, 7	10
1889	Treatment of lung cancer in the elderly patient. 2013 , 34, 802-9	7
1888	Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. 2013 , 5, 334-56	49
1887	Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. 2013 , 21, 326-36	27
1886	Targeting genomic alterations in squamous cell lung cancer. 2013 , 3, 195	15
1885	Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. 2013 , 66, 381-5	43
1884	Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis. 2013 , 2013, 243859	30
1883	Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. 2013 , 30, 191-8	54

1882	Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. 2013 , 3, 261	57
1881	Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. 2013 , 20, e150-60	25
1880	Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. 2013 , 86, 20120174	20
1879	Verifying the role of surgical pathologists in the precision medicine of lung cancer. 2013 , 137, 1176-8	2
1878	Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. 2013 , 50, 87-93	17
1877	[Regional molecular genetics centers in thoracic oncology: what and who should be tested?]. 2013 , 100, 737-41	1
1876	Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?. 2013 , 31, 2236-9	13
1875	Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). 2013 , 43, 664-8	29
1874	A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. 2013 , 41, 262-9	46
1873	Docetaxel and Cisplatin regimen for non-small-cell lung cancer. 2013 , 48, 550-7	2
1872	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. 2013 , 18, 1214-20	108
1871	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). 2013 , 24, 2371-6	350
1870	PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. 2013 , 23, 636-42	13
1869	The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. 2013 , 25, 121-9	9
1868	Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). 2013 , 24, 1615-22	92
1867	Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC. 2013 , 22, 138-43	11
1866	Actionable mutations in muscle-invasive bladder cancer. 2013 , 23, 472-8	15
1865	How and when to use genetic markers for nonsmall cell lung cancer. 2013 , 19, 331-9	9

1864	Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 2013 , 12, 2601-13	24
1863	Personalized Treatment of Lung Adenocarcinoma. 2013 , 20, 309-314	
1862	Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. 2013 , 36, 510-8	63
1861	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. 2013 , 3, 1404-15	493
1860	Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged sword. 2013 , 11, 1125-8	2
1859	ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. 2013 , 31, 3926-34	134
1858	Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). 2013 , 43, 629-35	13
1857	Erlotinib resistance in lung cancer cells mediated by integrin α /Src/Akt-driven bypass signaling. 2013 , 73, 6243-53	107
1856	Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. 2013 , 9, 271-81	16
1855	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. 2013 , 31, 3320-6	227
1854	Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. 2013 , 31, 3291-3	14
1853	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. 2013 , 24, 1326-31	51
1852	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. 2013 , 5, 249-70	34
1851	Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. 2013 , 3, 288-305	22
1850	Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. 2013 , 43, 919-24	22
1849	Methodological assessment of HCC literature. 2013 , 24 Suppl 2, ii6-14	1
1848	TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?. 2013 , 31, 288-9	4
1847	Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. 2013 , 6, 135-43	44

1846	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. 2013 , 14, 2171-82	13
1845	Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?. 2013 , 31, 3303-6	51
1844	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. 2013 , 19, 246-53	8
1843	Novel cancer therapies: treatments driven by tumour biology. 2013 , 89, 652-8	14
1842	Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. 2013 , 105, 589-90	2
1841	Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications. 2013 , 9, 261-6	5
1840	Emerging options for the management of non-small cell lung cancer. 2013 , 7, 221-34	14
1839	Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer. 2013 , 59, 99-105	6
1838	Salvage therapy beyond targeted therapy in lung adenocarcinoma. 2013 , 34, 837-44	5
1837	A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. 2013 , 2, 360-6	8
1836	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. 2013 , 119, 4325-32	152
1835	Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. 2013 , 104, 291-7	29
1834	Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. 2013 , 65, 1351-95	26
1833	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. 2013 , 105, 595-605	402
1832	Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. 2013 , 8, 1148-55	81
1831	Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. 2013 , 12, 3390-404	57
1830	Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. 2013 , 110, 15043-8	116
1829	Rare mutations in non-small-cell lung cancer. 2013 , 9, 699-711	17

1828	Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. 2013 , 12, 589-97	51
1827	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. 2013 , 3, 2459	56
1826	New treatment strategy for patients with EGFR-mutant lung cancer. 2013 , 2, 505-516	
1825	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. 2013 , 30, 1463-72	5
1824	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. 2013 , 2, 381-390	
1823	Chemotherapy of advanced non-small-cell lung cancer: current landscape. 2013 , 3, 265-279	
1822	The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer. 2013 , 3, 523-530	
1821	Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. 2013 , 8, 1136-41	35
1820	Combined treatment with erlotinib and a transforming growth factor- α type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. 2013 , 8, 259-69	33
1819	KRAS mutations predict sensitivity to pemetrexed-based chemotherapy. 2013 , 2, 275-280	4
1818	Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. 2013 , 8, 408-14	36
1817	Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective. 2013 , 2, 309-315	1
1816	Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. 2013 , 8, 45-51	114
1815	Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. 2013 , 43, 1045-51	26
1814	Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels. 2013 , 6, 602-8	3
1813	Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. 2013 , 8, 1059-68	38
1812	A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. 2013 , 11, 389-94	12
1811	Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study. 2013 , 8, 1474-83	24

1810	Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. 2013 , 2, 89-92	
1809	Epidermal growth factor receptor inhibition in lung cancer: status 2012. 2013 , 8, 373-84	99
1808	Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. 2013 , 8, 96-101	46
1807	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. 2013 , 8, 346-51	240
1806	Rebuttal from Dr Lam. 2013 , 143, 603-604	
1805	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of clinical practice. 2013 , 10, 129-131	1
1804	Patient versus clinician preferences for chemotherapy in non-small-cell lung cancer. 2013 , 2, 527-536	1
1803	BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. 2013 , 8, 295-300	17
1802	Molecular subtypes of non-small-cell lung cancer. 2013 , 6-20	1
1801	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. 2013 , 11, 161-9	50
1800	Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. 2013 , 5, 137-41	
1799	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. 2013 , 6, 1771-7	7
1798	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. 2013 , 5, 91-101	13
1797	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. 2013 , 4, 736-54	65
1796	The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. 2013 , 54, 1-14	16
1795	Can microRNAs improve the management of lung cancer patients? A clinician's perspective. 2013 , 3, 953-63	17
1794	EGFR inhibitors: patient selections and clinical outcome. 2013 , 160-176	
1793	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. 2013 , 6, 563-76	20

1792	MET overexpression and gene amplification in NSCLC: a clinical perspective. 2013 , 4, 15-25	5
1791	Development of personalized treatments in lung cancer: focusing on the mutations and beyond. 2013 , 4, 43-53	3
1790	Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations. 2013 , 28, 249-58	8
1789	The economic evaluation of personalised oncology medicines: ethical challenges. 2013 , 199, 471-3	16
1788	The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations. 2013 , 32, 136-40	5
1787	A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. 2013 , 8, e55917	39
1786	Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. 2013 , 8, e70346	28
1785	Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. 2013 , 8, e72692	25
1784	Frequency of EGFR mutations in 907 lung adenocarcinoma patients of Indian ethnicity. 2013 , 8, e76164	70
1783	Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. 2013 , 8, e84700	38
1782	Systemic cancer therapy: achievements and challenges that lie ahead. 2013 , 4, 57	125
1781	Tailored therapy in lung cancer. 2013 , 20, 367-8	1
1780	[Diagnosis of brain metastases: an update in 2012]. 2013 , 100, 29-34	1
1779	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. 2013 , 7, 61-8	26
1778	Nedaplatin: a cisplatin derivative in cancer chemotherapy. 2013 , 5, 67-76	69
1777	Lung cancer in 2013: state of the art therapy for metastatic disease. 2013 , 339-46	8
1776	Evaluation of Simple Suspension Method for Erlotinib Dosing and Its Pharmacokinetic Profile in Patients with Non-Small Cell Lung Cancer. 2013 , 39, 565-570	
1775	Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. 2014 , 47, 929-39	77

1774	Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. 2014 , 7, 253-61	1
1773	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. 2014 , 7, 1689-704	54
1772	Clinical and comparative utility of afatinib in non-small cell lung cancer. 2014 , 8, 183-92	22
1771	Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. 2014 , 9, e114000	23
1770	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. 2014 , 9, e103883	120
1769	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. 2014 , 9, e85245	97
1768	Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. 2014 , 9, e95303	47
1767	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. 2014 , 9, e107161	110
1766	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. 2014 , 9, e110780	109
1765	Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases. 2014 , 7, 97-101	3
1764	Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. 2014 , 1, GRHTA.5000182	8
1763	Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. 2014 , 4, 297-310	13
1762	Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. 2014 , 5, 1048-54	45
1761	EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. 2014 , 7, 2075-84	30
1760	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. 2014 , 8, 1037-46	9
1759	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. 2014 , 8, 1595-611	31
1758	Targeted treatment of mutated -expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. 2014 , 5, 73-79	1
1757	Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer. 2014 , 4,	

1756	Single-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off Probes. 2014 , 5, 1000175	1
1755	Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation. 2014 , 76, 8-14	4
1754	The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. 2014 , 33, 105-14	6
1753	Molecular Targeted Therapy in Lung Cancer. 2014 , 34, 37	1
1752	Management and future directions in non-small cell lung cancer with known activating mutations. 2014 , e353-65	62
1751	50 Years of progress in the systemic therapy of non-small cell lung cancer. 2014 , 177-89	75
1750	Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. 2014 , 32, 1311-5	24
1749	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. 2014 , 14, 807-15	14
1748	Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population. 2014 , 7, 795-9	8
1747	Development in the diagnostic lung cancer pathway: implication for treatment. 2014 , 3, 417-428	1
1746	A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. 2014 , 120, 423-30	32
1745	Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC. 2014 , 3, 459-476	1
1744	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. 2014 , 4, 1036-45	302
1743	Tumor acquisition for biomarker research in lung cancer. 2014 , 32, 291-8	3
1742	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. 2014 , 74, 939-46	10
1741	Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. 2014 , 74, 661-5	20
1740	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. 2014 , 2, 9	12
1739	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive [®]) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. 2014 , 14, 748	74

1738	Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. 2014 , 122, 822-32	47
1737	Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report. 2014 , 8, 335	8
1736	A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. 2014 , 20, 1644-55	41
1735	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. 2014 , 106,	88
1734	Management of NSCLC: focus on crizotinib. 2014 , 15, 2587-97	13
1733	Evaluating the utility of local therapy for oligometastatic lung cancer. 2014 , 3, 373-381	
1732	Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. 2014 , 111, 843-50	18
1731	Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors. 2014 , 3, 101-116	
1730	Successes and limitations of targeted cancer therapy in lung cancer. 2014 , 41, 62-77	26
1729	The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. 2014 , 3, 209-17	2
1728	Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. 2014 , 27, 1621-31	13
1727	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. 2014 , 10, 2081-96	13
1726	First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. 2014 , 23, 92-105	32
1725	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. 2014 , 110, 55-62	282
1724	The role of systemic and targeted therapies in brain metastases. 2014 , 14, 93-103	6
1723	Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. 2014 , 16 Suppl 8, viii7-13	71
1722	The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. 2014 , 14, 955-64	14
1721	Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. 2014 , 90, 228-35	4

1720	Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. 2014 , 4, 253	24
1719	Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. 2014 , 21, 329-36	54
1718	The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach. 2014 , 4, 178	10
1717	The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. 2014 , 120, 3853-8	8
1716	Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice. 2014 , 2014, 987150	0
1715	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. 2014 , 4, 242	53
1714	Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs. 2014 , 4, 238	50
1713	Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases. 2014 , 7, 357-360	24
1712	Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. 2014 , 4, 190	39
1711	Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer. 2014 , 4, 281	23
1710	Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. 2014 , 7, 2180-2184	10
1709	Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib. 2014 , 8, 2699-2704	6
1708	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. 2014 , 4, 204	111
1707	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. 2014 , 4, 233	11
1706	Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. 2014 , 138, 171-4	15
1705	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. 2014 , 23, 367-78	60
1704	Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer. 2014 , 37, 262-5	4
1703	Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer. 2014 , 60, 180-4	2

1702	Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. 2014 , 10, 813-22	10
1701	[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. 2014 , 139, 2096-100	6
1700	[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients]. 2014 , 68, 619-23	
1699	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. 2014 , 10, 1081-93	5
1698	Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors. 2014 , 3, 77-84	
1697	Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. 2014 , 22, 401-7	12
1696	Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. 2014 , 122, 104-13	90
1695	In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. 2014 , 13, 1468-79	56
1694	EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review. 2014 , 406-420	
1693	One-pot room-temperature conversion of cyclohexane to adipic acid by ozone and UV light. 2014 , 346, 1495-8	63
1692	MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses. 2014 , 346, 1486-92	87
1691	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. 2014 , 25, 1475-84	174
1690	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. 2014 , 15, 2693-708	18
1689	Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods. 2014 , 65, 539-48	27
1688	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. 2014 , 120, 3896-901	151
1687	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014 , 371, 2167-77	2116
1686	Smarter drugs emerging in pancreatic cancer therapy. 2014 , 25, 1260-1270	62
1685	Scientific Exhibits. 2014 , 58, 184-343	

1684	Evolutionarily conserved stress responses as potential anticancer therapeutic targets? (Comment on DOI 10.1002/bies.201300170). 2014 , 36, 544-5	
1683	A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. 2014 , 57, 9889-900	44
1682	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. 2014 , 4, 1046-61	1242
1681	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. 2014 , 20, 1383-92	121
1680	Hallazgo radiológico en mujer fumadora de 65 años. 2014 , 11, 4050.e1-4050.e3	
1679	Câncer de pulmão. 2014 , 11, 3983-3994	
1678	Abstracts from the 2014 Combined Scientific Meeting: Imaging and Radiation in Personalised Medicine. 4-7 September 2014, Melbourne Convention and Exhibition Centre, Melbourne, Australia. This supplement is a joint publication with the Journal of Medical Imaging & Radiation Oncology: Vol. 58, Suppl. 1, September 2014, Pages 1-352. 2014 , 61 Suppl 1, 184-343	
1677	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. 2014 , 111, 2067-75	35
1676	Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. 2014 , 120, 2090-8	49
1675	Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. 2014 , 10 Suppl 2, 2-10	3
1674	Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. 2014 , 19, 1100-9	20
1673	The evolving genomic classification of lung cancer. 2014 , 232, 121-33	74
1672	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. 2014 , 44, 1011-22	46
1671	Stigma among patients with lung cancer: a patient-reported measurement model. 2014 , 23, 81-92	78
1670	Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. 2014 , 31, 220	5
1669	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014 , 25 Suppl 3, iii27-39	521
1668	The oligometastatic state - separating truth from wishful thinking. 2014 , 11, 549-57	178
1667	Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. 2014 , 18, 1519-39	28

1666	Pharmacotherapy targeting the EGFR oncogene in NSCLC. 2014 , 15, 2293-305	16
1665	Management of non-small cell lung cancer in the elderly. 2014 , 25, 888-94	6
1664	Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. 2014 , 86, 86-93	14
1663	Clinical Pharmacogenetics. 2014 , 803-821	
1662	Frñe palliative Intervention. 2014 , 20, 998-1002	1
1661	Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?. 2014 , 25, 1283-1293	14
1660	A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. 2014 , 14, 684	10
1659	Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells. 2014 , 12, 367	9
1658	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma. 2014 , 9, 103	4
1657	Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. 2014 , 12, 355	16
1656	Strategies for modern biomarker and drug development in oncology. 2014 , 7, 70	87
1655	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. 2014 , 9, 1171-9	57
1654	Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. 2014 , 9, 189-94	140
1653	An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. 2014 , 9, 631-8	120
1652	Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays. 2014 , 9, 91-6	10
1651	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 2014 , 13, 535-49	22
1650	Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. 2014 , 9, 109-13	13
1649	Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. 2014 , 9, 1669-74	83

1648	Novel drugs against non-small-cell lung cancer. 2014 , 26, 145-51	21
1647	EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma. 2014 , 46, 32-6	
1646	EGFR mutation and brain metastasis in pulmonary adenocarcinomas. 2014 , 9, 195-9	170
1645	Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. 2014 , 9, 200-4	43
1644	Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. 2014 , 9, 805-11	71
1643	Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. 2014 , 9, 1426-33	42
1642	Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. 2014 , 9, 717-24	43
1641	ALK inhibitors and advanced non-small cell lung cancer (review). 2014 , 45, 499-508	30
1640	EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. 2014 , 4, 350	9
1639	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. 2014 , 14, 1495-513	6
1638	Changing the paradigm: circulating tumor DNA as a "liquid biopsy" for clinical biomarker assessments. 2014 , 4, 1083-1093	1
1637	Convex probe endobronchial ultrasound. 2014 , 35, 636-44	5
1636	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. 2014 , 25, 1681-1690	208
1635	Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. 2014 , 5, 646-59	15
1634	Preparation of cell blocks for lung cancer diagnosis and prediction: protocol and experience of a high-volume center. 2014 , 87, 432-8	20
1633	Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. 2014 , 311, 1975-6	20
1632	Erlotinib. 2014 , 201, 109-23	10
1631	Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. 2014 , 4, 244	49

1630	The management of brain metastases in non-small cell lung cancer. 2014 , 4, 248	44
1629	Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. 2014 , 4, 256	13
1628	Histological subtype and smoking status, but not gender, are associated with mutations in non-small-cell lung cancer. 2014 , 2, 252-258	10
1627	Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. 2014 , 2, 991-996	6
1626	Role of rapid on-site evaluation with cyto-histopathological correlation in diagnosis of lung lesion. 2014 , 31, 189-93	22
1625	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. 2014 , 23, 356-66	105
1624	Therapeutic use of microRNAs in lung cancer. 2014 , 2014, 756975	34
1623	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. 2014 , 9, 261	9
1622	Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. 2014 , 20, 4647-59	93
1621	Overall response to first-line tyrosine kinase inhibitor and second-line chemotherapy is predictive of survival outcome in epidermal growth factor receptor-mutated adenocarcinoma. 2014 , 60, 201-10	4
1620	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. 2014 , 10, 21-40	11
1619	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). 2014 , 9, 154-62	757
1618	Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. 2014 , 9, 506-11	38
1617	Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review. 2014 , 9, 1180-6	21
1616	NSCLC and HER2: between lights and shadows. 2014 , 9, 1750-62	43
1615	Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. 2014 , 29, 357-63	51
1614	High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer. 2014 , 44, 1188-92	12
1613	Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. 2014 , 110, 126-31	33

1612 Erlotinib: Lacking of Cholinergic Effects on Tracheal Smooth Muscle. **2014**, 6, 98-101

1611	Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. 2014 , 83, 329-33		36
1610	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. 2014 , 50, 1717-1721		10
1609	Treatment for early-stage lung cancer: what next?. 2014 , 383, 1528-30		7
1608	management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. 2014 , 15, 307-12		22
1607	Targeting epidermal growth factor receptor in the management of lung cancer. 2014 , 41, 101-9		19
1606	Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. 2014 , 85, 66-73		44
1605	Invasive and noninvasive advances in the staging of lung cancer. 2014 , 41, 17-27		2
1604	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 713-21	21.7	131
1603	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. 2014 , 90, 135-45		11
1602	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). 2014 , 83, 174-81		36
1601	Extending survival of stage IV non-small cell lung cancer. 2014 , 41, 69-92		32
1600	Diacylglycerol kinase β modulates oncogenic properties of lung cancer cells. 2014 , 16, 29-35		18
1599	Application of Translational Science to Clinical Development. 2014 , 1-21		
1598	Targeted therapies in brain metastases. 2014 , 16, 276		38
1597	Prognostic and predictive biomarkers in lung cancer. A review. 2014 , 464, 347-58		65
1596	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. 2014 , 2, 2		19
1595	Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. 2014 , 464, 61-8		77

1594	Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. 2014 , 31, 810		13
1593	The impact of germline mutations on targeted therapy. 2014 , 232, 230-43		6
1592	Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. 2014 , 40, 723-9		17
1591	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. 2014 , 84, 39-44		103
1590	EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. 2014 , 83, 224-30		33
1589	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. 2014 , 40, 93-101		97
1588	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. 2014 , 83, 231-9		78
1587	Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug. 2014 , 15, 145-51		16
1586	Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. 2014 , 40, 197-203		26
1585	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 213-22	21.7	1395
1584	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. 2014 , 83, 211-8		53
1583	Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. 2014 , 383, 1561-71		363
1582	Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. 2014 , 21, 2091-6		55
1581	Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs). 2014 , 7, 10-15		
1580	The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. 2014 , 73, 613-21		30
1579	Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. 2014 , 140, 427-33		8
1578	Lung cancer in never smokers: a different disease. 2014 , 3, 26-34		5
1577	Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. 2014 , 32, 195-9		30

1576	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. 2014 , 73, 299-307	24
1575	Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. 2014 , 35, 4921-8	14
1574	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. 2014 , 89, 300-13	56
1573	Targeted therapies in gastroesophageal cancer. 2014 , 50, 1247-58	41
1572	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. 2014 , 120, 2289-98	25
1571	ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. 2014 , 25, 282-303	631
1570	Molecular profiling of small cell lung cancer in a Japanese cohort. 2014 , 84, 139-44	29
1569	Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. 2014 , 40, 648-55	88
1568	Beyond histology: translating tumor genotypes into clinically effective targeted therapies. 2014 , 20, 2264-75	51
1567	Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). 2014 , 83, 265-71	33
1566	Molecular Testing in Cancer. 2014 ,	1
1565	Pharmacogenomics and Personalized Medicines in Cancer Treatment. 2014 , 55-90	
1564	Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. 2014 , 95, 269-80	53
1563	Protein kinase inhibitors to treat non-small-cell lung cancer. 2014 , 15, 1203-13	16
1562	EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy. 2014 , 15, 387-9	5
1561	Recent clinical advances in lung cancer management. 2014 , 32, 973-82	169
1560	DNA sequencing of cancer: what have we learned?. 2014 , 65, 63-79	37
1559	Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. 2014 , 9, 77-92	21

1558	Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VeriFAST platform. 2014 , 14, 99-105	20
1557	Emerging technologies for hybridization based single nucleotide polymorphism detection. 2014 , 139, 353-70	57
1556	The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. 2014 , 40, 485-94	19
1555	Targeted therapy-induced diarrhea: A review of the literature. 2014 , 90, 165-79	37
1554	Biomarker enrichment strategies: matching trial design to biomarker credentials. 2014 , 11, 81-90	121
1553	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. 2014 , 20, 2001-10	182
1552	Molecularly targeted cancer therapy: some lessons from the past decade. 2014 , 35, 41-50	206
1551	A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. 2014 , 83, 73-7	8
1550	New treatment options for lung adenocarcinoma--in view of molecular background. 2014 , 20, 11-25	26
1549	MicroRNAs and cancer stem cells: the sword and the shield. 2014 , 33, 4967-77	109
1548	Towards defining biomarkers indicating resistances to targeted therapies. 2014 , 1844, 909-16	9
1547	Efficiency of the Therascreen [®] RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. 2014 , 429, 8-11	36
1546	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1433-1441	217 92
1545	Guide to Targeted Therapies: EGFR mutations in NSCLC. 2014 ,	
1544	Maladie oligométastatique dans le cancer bronchique non ^petites cellules. 2014 , 6, 495-501	
1543	Aspects biologiques des cancers bronchiques. 2014 , 6, 311-319	
1542	Thérapies ciblées : quel traitement pour quel patient ?. 2014 , 6, 459-469	
1541	Carcinome bronchique non ^petites cellules : quelle chimiothérapie de rattrapage ?. 2014 , 6, 442-452	

1540	Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. 2014 , 105, 1023-31	18
1539	The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. 2014 , 134, 2314-21	22
1538	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. 2014 , 346, 1480-6	507
1537	Nintedanib for the treatment of non-small-cell lung cancer. 2014 , 15, 729-39	11
1536	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. 2014 , 10, 533-40	6
1535	Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. 2014 , 190, 1127-38	42
1534	Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). 2014 , 86, 170-3	112
1533	Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. 2014 , 86, 219-24	14
1532	A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). 2014 , 86, 195-200	6
1531	Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. 2014 , 86, 213-8	20
1530	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 2014 , 15, 411-417.e4	28
1529	A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. 2014 , 32, 1226-35	8
1528	Novel agents in development for advanced non-small cell lung cancer. 2014 , 6, 240-53	26
1527	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 2014 , 14, 453-68	16
1526	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. 2014 , 15, 453	139
1525	Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment. 2014 , 55, 1417-23	16
1524	Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. 2014 , 20, 4193-9	20
1523	Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. 2014 , 15, 441-7	30

1522	Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. 2014 , 41, 749-57		32
1521	Reply to B.M. Strebels. 2014 , 32, 479-80		
1520	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous non-small-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. 2014 , 25, 2385-2391		46
1519	Update on systemic therapy of advanced non-small-cell lung cancer. 2014 , 14, 1189-203		19
1518	Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. 2014 , 7, 341-8		60
1517	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. 2014 , 23, 1333-48		41
1516	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. 2014 , 86, 102-4		21
1515	New strategies in lung cancer: translating immunotherapy into clinical practice. 2014 , 20, 1067-73		36
1514	What new therapeutic targets exist for EGFR-mutant NSCLC?. <i>Lancet Oncology, The</i> , 2014 , 15, 1184-5	21.7	2
1513	Mise au point 2014 du cancer bronchique non ^petites cellules (en dehors du d'pistage). 2014 , 95, 708-712		
1512	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. 2014 , 40, 917-26		103
1511	Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture. 2014 , 67, 125-131		13
1510	Targeted therapy in older patients with solid tumors. 2014 , 32, 2635-46		31
1509	Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. 2014 , 11, 627-8		23
1508	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 1236-44	21.7	524
1507	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. 2014 , 20, 5898-907		67
1506	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. 2014 , 31, 78		4
1505	Neue Substanzen ff die Therapie solider Tumoren. 2014 , 29, 300-304		

1504 Lung Cancer in Older Adults. **2014**, 3, 166-174

1503	Large cell carcinoma of lung: On the verge of extinction?. 2014 , 31, 278-88		18
1502	Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?. 2014 , 32, 859-63		2
1501	Afatinib-related nonhematologic adverse events: is common evaluation enough for now?. 2014 , 32, 864-5		3
1500	Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre. 2014 , 98, 92-8		46
1499	Combination of stereotactic ablative body radiation with targeted therapies. <i>Lancet Oncology, The</i> , 2014 , 15, e426-34	21.7	28
1498	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. 2014 , 25, 126-31		208
1497	VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?. 2014 , 8, 1-4		9
1496	Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. 2014 , 140, 2097-105		7
1495	Non-small-cell lung cancer in elderly patients: a discussion of treatment options. 2014 , 32, 2562-9		27
1494	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. 2014 , 92, 697-707		47
1493	Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. 2014 , 63, 737-47		7
1492	Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. 2014 , 73, 943-50		8
1491	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. 2014 , 73, 1063-70		16
1490	Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. 2014 , 41, 40-56		40
1489	A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. 2014 , 14, 517-24		20
1488	Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). 2014 , 50, 302-8		20
1487	A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. 2014 , 16, 45-55		27

1486	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. 2014 , 23, 1527-37	13
1485	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. 2014 , 20, 4613-24	171
1484	2014 update on non-small cell lung cancer (excluding diagnosis). 2014 , 95, 721-5	8
1483	Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. 2014 , 9, 381-8	24
1482	EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. 2014 , 9, 389-94	3
1481	A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. 2014 , 31, 36	5
1480	Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. 2014 , 16, 339-50	21
1479	Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. 2014 , 32, 651-80	19
1478	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. 2014 , 13, 143	45
1477	Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report. 2014 , 8, 102	4
1476	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. 2014 , 10, 1065-80	8
1475	Acquired resistance to TKIs in solid tumours: learning from lung cancer. 2014 , 11, 473-81	591
1474	From cancer genomics to precision oncology--tissue's still an issue. 2014 , 157, 1509-14	24
1473	Understanding lung cancer molecular subtypes. 2014 , 11, 441-453	1
1472	Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. 2014 , 59, 308-13	19
1471	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. 2014 , 111, 413-20	36
1470	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. 2014 , 39, 465-74	110
1469	Current concepts on the molecular pathology of non-small cell lung carcinoma. 2014 , 31, 306-13	31

1468	State of the art: Response assessment in lung cancer in the era of genomic medicine. 2014 , 271, 6-27	92
1467	Emerging drugs targeting PD-1 and PD-L1: reality or hope?. 2014 , 19, 557-69	10
1466	Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control Study. 2014 , 7, 508-12	3
1465	Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). 2014 , 86, 54-8	3
1464	[Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013]. 2014 , 70, 38-46	
1463	Emerging protein kinase inhibitors for non-small cell lung cancer. 2014 , 19, 51-65	21
1462	Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. 2014 , 15, 1-6	67
1461	Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. 2014 , 45, 1162-8	14
1460	Pathologie avancèe et d'effaillances d'organes: outil d'aide à la d'cision. 2014 , 13, 150-154	1
1459	Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?. 2014 , 84, 97-100	17
1458	Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. 2014 , 2, 4-7	1
1457	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. 2014 , 15, 173-81	50
1456	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. 2014 , 15, 338-45.e1	6
1455	Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. 2014 , 52, 49-56	5
1454	SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. 2014 , 85, 1-6	24
1453	Afatinib in NSCLC harbouring EGFR mutations. <i>Lancet Oncology, The</i> , 2014 , 15, e148-9	21.7 6
1452	Surviving with lung cancer: medication-taking and oral targeted therapy. 2014 , 35, S49-56	10
1451	Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. 2014 , 15, 202-6	55

1450	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. 2014 , 326, 201-9	5
1449	Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. 2014 , 85, 161-7	36
1448	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. 2014 , 40, 716-22	106
1447	Information technology and precision medicine. 2014 , 30, 124-9	11
1446	Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing. 2014 , 26, 468-72	3
1445	[Afatinib (BIBW 2992)]. 2014 , 70, 279-85	2
1444	Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. 2014 , 21, 396-405	14
1443	Afatinib in the treatment of EGFR mutation-positive NSCLC—a network meta-analysis. 2014 , 85, 230-8	40
1442	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. 2014 , 19, 1671-6	30
1441	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. 2014 , 40, 990-1004	60
1440	Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. 2014 , 48, 361-8	14
1439	Changing histopathological diagnostics by genome-based tumor classification. 2014 , 5, 444-59	12
1438	Review of the current targeted therapies for non-small-cell lung cancer. 2014 , 5, 576-87	50
1437	Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials. 2014 , 20, 2666-76	14
1436	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. 2014 , 7, 285-95	24
1435	A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. 2014 , 9, 577-82	22
1434	Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. 2014 , 31, 2015-20	9
1433	Epidermal growth factor receptor inhibitors: coming of age. 2014 , 21, 74-9	51

1432	Systemic and targeted therapies for early-stage lung cancer. 2014 , 21, 21-31	17
1431	Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. 2014 , 21, 32-9	5
1430	Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation. 2014 , 87, 215-23	10
1429	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?. 2014 , 9, e19-20	2
1428	Predictive Tumor Biomarkers for EGFR Inhibitors. 2014 , 435-453	2
1427	Pathology of Adenocarcinoma. 2014 , 144-157	
1426	Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. 2014 , 1, 81-94	5
1425	Afatinib: rationale for use in non-small-cell lung cancer based on clinical trial data. 2014 , 4, 55-61	1
1424	Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?. 2014 , 9, e49-e50	16
1423	Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. 2013 , 21, 137-44	33
1422	Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). 2014 , 9, 1411-7	12
1421	A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib. 2014 , 9, e47-8	
1420	Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations. 2014 , 21, 67-73	12
1419	Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy. 2014 , 7, 583-90	3
1418	Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. 2014 , 21, 90-7	5
1417	Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. 2014 , 3, 85-99	
1416	The Role of ERBB Family Blockade in NSCLC. 2014 , 2, 51-58	
1415	Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. 2014 , 3, 477-489	

1414	Germline EGFR T790M mutation found in multiple members of a familial cohort. 2014 , 9, 554-8	47
1413	Third-line systemic treatment for non-small cell lung cancer. 2014 ,	78
1412	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. 2015 , 10, 903-9	26
1411	Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. 2015 , 4, 174-181	22
1410	Towards manageable toxicities from targeted lung cancer treatment. 2015 , 4, 279-287	
1409	Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. 2015 , 10, 1268-1278	49
1408	The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials. 2015 , 94, e1400	6
1407	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. 2015 , 10, 738-746	63
1406	Novel targeted agents for the treatment of lung cancer in China. 2015 , 121 Suppl 17, 3089-96	7
1405	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. 2015 , 20, 199-208	3
1404	Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. 2015 , 121 Suppl 17, 3069-79	41
1403	Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma. 2015 , 6, 678-86	3
1402	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. 2015 , 278, 545-70	38
1401	Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure. 2015 , 10, e115-8	2
1400	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. 2015 , 10, 1754-61	96
1399	A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. 2015 , 10, 1575-1578	9
1398	Targeted Therapy in Solid Tumors: Lung Cancer. 2015 , 224-230	
1397	L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report. 2015 , 10, 1293-1296	7

1396	The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. 2015 , 5, 11348	18
1395	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. 2015 , 5, 17499	40
1394	Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. 2015 , 5, 24	15
1393	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. 2015 , 5, 12675	11
1392	A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. 2015 , 33, 1040-8	7
1391	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. 2014 , 4, 7268	24
1390	Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. 2015 , 54, 1977-80	27
1389	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. 2015 , 46, 497-504	15
1388	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. 2015 , 10, 1364-1369	10
1387	ER α localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. 2015 , 5, 11392	15
1386	Non-Small Cell Lung Cancer, Version 6.2015. 2015 , 13, 515-24	268
1385	Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells. 2015 , 7, 25-32	7
1384	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. 2015 , 10, 33-40	7
1383	Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. 2015 , 47, 320-8	16
1382	Heterogeneity of EGFR mutations in a patient treated with gefitinib as neo-adjuvant chemotherapy. 2015 , 4, 117-120	
1381	Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. 2015 , 10, 1553-9	109
1380	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. 2015 , 17, 1020-9	37
1379	The relevance of positron emission tomography response in non-small cell lung cancer. 2015 , 8, 119-129	0

1378	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. 2015 , 34, 310-9	8
1377	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. 2015 , 13, 763	13
1376	Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status. 2015 , 10, 99	19
1375	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. 2015 , 121, 3298-306	27
1374	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. 2015 , 137, 2947-58	7
1373	Targeted Therapy for Cancer in the Genomic Era. 2015 , 21, 294-8	34
1372	Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. 2015 , 13, 257	17
1371	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. 2015 , 121, 3212-3220	119
1370	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. 2015 , 10, 55-68	22
1369	Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question. 2015 , 101, e115-7	4
1368	From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. 2015 , 21, 413-24	2
1367	The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth. 2015 , 30, 308-13	11
1366	Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. 2015 , 40, 661-71	9
1365	Increase EGFR Mutations Detection Rate in Lung Adenocarcinoma by Real-Time PCR Screening Followed by Direct Sequencing. 2015 , 23, 343-8	7
1364	Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice. 2015 , 21, 404-12	18
1363	Adequacy of Malignant Pleural Effusion for Epidermal Growth Factor Receptor Mutation Analysis Using the Pyrosequencing Method. 2015 , 2, 237399751561658	2
1362	IMPRESS is impressive. 2015 , 4, 51-53	1
1361	Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. 2015 , 21, 371-7	34

1360	New generations of targeted therapies fighting the resistance in solid tumors. 2015 , 27, 243-9	3
1359	Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. 2015 , 26, 995-1003	12
1358	The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis. 2015 , 94, e1719	8
1357	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis. 2015 , 30, 300-7	8
1356	Status quo in der Zweitlinientherapie des NSCLC und Ausblick in die Zukunft. 2015 , 38, I-VI	
1355	The Evolution of Therapies in Non-Small Cell Lung Cancer. 2015 , 7, 1815-46	81
1354	The Continuation of Erlotinib Treatment in Non-Small Cell Lung Cancer Patients Whose Brain Lesion Is the Only Site of Progression: Prospective Pilot Study. 2015 , 35, 180	
1353	Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified. 2015 , 22, e164-70	17
1352	An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. 2015 , 8, 1351-4	6
1351	The distinctive nature of adenocarcinoma of the lung. 2015 , 8, 2399-406	12
1350	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. 2015 , 6, 30850-8	62
1349	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. 2015 , 8, 63-79	21
1348	Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer. 2015 , 8, 893-8	13
1347	Afatinib for the treatment of metastatic non-small cell lung cancer. 2015 , 7, 75-82	26
1346	EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. 2015 , 8, 3017-20	8
1345	The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. 2015 , 13, 215-20	2
1344	miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. 2015 , 9, 569	11
1343	Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. 2015 , 10, 1135-1140	5

1342	Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. 2015 , e165-73	13
1341	The Future of Molecular Medicine: Biomarkers, BATTLEs, and Big Data. 2015 , 22-7	6
1340	Outcome of crizotinib treatment in a young woman with heavily pretreated ROS1-positive lung cancer. 2015 , 101, e103-6	3
1339	Epiregulin as a therapeutic target in non-small-cell lung cancer. 2015 , 6, 91-98	12
1338	Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. 2015 , 6, 568-74	15
1337	Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?. 2015 , 9, 5641-53	21
1336	EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?. 2015 , 8, 2915-21	12
1335	Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?. 2015 , 22, 272-8	8
1334	Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. 2015 , 10, e0121211	14
1333	Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. 2015 , 10, e0123901	10
1332	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. 2015 , 10, e0134346	56
1331	Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. 2015 , 8, 1137-42	19
1330	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. 2015 , 41, 365-75	19
1329	Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. 2015 , 8, 905-10	11
1328	Associations of LIG4 and HSPB1 genetic polymorphisms with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy. 2015 , 2015, 860373	4
1327	Combination of EGFR-TKI and Platinum-based Therapy for EGFR-mutated Non-small Cell Lung Cancer. 2015 , 55, 871-878	
1326	. 2015 ,	2
1325	Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. 2015 , 6, 18224-37	62

1324	Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. 2015 , 19, 734-42	3
1323	KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives. 2015 , 15, 418-32	32
1322	A Phase III Study Comparing Gefitinib and Inserted Platinum-doublet Chemotherapy with Gefitinib as a First-line Treatment for Patients with Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Activating Mutations. 2015 , 55, 879-884	
1321	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. 2015 , 6, 26814-25	117
1320	Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). 2015 , 45, 670-6	21
1319	Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature. 2015 , 37, 2-21	28
1318	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. 2015 , 6, 6377	358
1317	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. 2015 , 20, 12-28	78
1316	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. 2015 , 21, 2221-6	59
1315	Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. 2015 , 20, 1122-9	8
1314	Molekular stratifizierte Therapie und patientenrelevante Endpunkte. 2015 , 30, 122-126	1
1313	Clinical Trials of Mitotic Kinesin Inhibitors. 2015 , 63-76	1
1312	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. 2015 , 11, 1109-22	16
1311	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. 2015 , 21, 3924-33	344
1310	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology, The</i> , 2015 , 16, 830-8	21.7 551
1309	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. 2015 , 11, 1611-23	70
1308	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. 2015 , 7, 107-21	8
1307	EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF- κ B. 2015 , 463, 95-101	104

1306	Genomic medicine and targeted therapy for solid tumors. 2015 , 111, 38-42	12
1305	New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. 2015 , 129-154	
1304	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. 2015 , 89, 1227-40	28
1303	A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. 2015 , 75, 1229-36	5
1302	Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. 2015 , 76, 155-61	26
1301	Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A reevaluation based on meta-analysis. 2015 , 141, 1427-39	9
1300	Frñe palliative Intervention. 2015 , 18, 46-50	
1299	New strategies to develop new medications for lung cancer and metastasis. 2015 , 34, 265-75	10
1298	Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. 2015 , 88, 139-46	25
1297	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. 2015 , 88, 117-23	35
1296	Crizotinib in the management of advanced-stage non-small-cell lung cancer. 2015 , 11, 735-45	10
1295	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. 2015 , 9, 242-50	35
1294	Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. 2015 , 4, 171	21
1293	Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. 2015 , 33, 1008-14	134
1292	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. 2015 , 21, 3913-23	256
1291	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. 2015 , 5, 960-971	142
1290	Targeting EGFR in lung cancer: Lessons learned and future perspectives. 2015 , 45, 67-73	34
1289	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. 2015 , 33, 2197-204	224

1288	Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer. 2015 , 372, 2137-47	5
1287	Experience with erlotinib in the treatment of non-small cell lung cancer. 2015 , 9, 146-63	19
1286	Necitumumab for non-small cell lung cancer. 2015 , 15, 1231-9	14
1285	Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. 2015 , 10, 1370-1374	21
1284	Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA). 2015 , 94, e1306	18
1283	Carcinomes bronchiques non ^petites cellules (CBNPC) mēastatiques, mutē ou rārrangē : comment dēterminer la cible ?. 2015 , 7, 476-496	1
1282	Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2015 , 94, e2239	5
1281	Afatinib for the treatment of non-small cell lung cancer. 2015 , 3, 1357-1364	1
1280	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. 2015 , 106, 1202-11	74
1279	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. 2015 , 15, 1605-29	21
1278	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). 2015 , 4, e1049804	34
1277	Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis. 2015 , 2, e000075	4
1276	Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations. 2015 , 46, 19-21	
1275	Prise en charge des patients de Performans Status 2 atteints d'un cancer bronchique non ^petites cellules mēastatique. 2015 , 7, 519-523	
1274	Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. 2015 , 10, 1172-80	27
1273	Cancers bronchiques non ^petites cellules mutē ou rārrangē : de la premiere lāa hīme ligne. 2015 , 7, 497-505	
1272	Ciblage de MET, T790M et ROS1. 2015 , 7, 506-510	
1271	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. 2015 , 10, 793-799	139

1270	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. 2015 , 10, 1396-403	57
1269	Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. 2015 , 38, 560-9	5
1268	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. 2015 , 10, 1341-1348	13
1267	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. 2015 , 10, 784-792	14
1266	Une << population spçiale >> : les sujets ¶š. 2015 , 7, 524-530	
1265	Indications de rànimation en oncologie thoracique. 2015 , 7, 545-553	1
1264	Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3. 2015 , 46, 2083-95	19
1263	Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer. 2015 , 148, 1063-1072	15
1262	Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. 2015 , 89, 275-80	12
1261	EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. 2015 , 34, 1375-83	27
1260	Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. 2015 , 16, 193-9	12
1259	An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. 2015 , 357, 364-373	7
1258	Developing biomarker-specific end points in lung cancer clinical trials. 2015 , 12, 135-46	36
1257	Oligometastases: Defined by prognosis and evaluated by cure. 2015 , 3, 1-6	16
1256	EGFR T790M resistance mutation in non small-cell lung carcinoma. 2015 , 444, 81-5	57
1255	Genomic profiling of small-cell lung cancer: the era of targeted therapies. 2015 , 45, 513-9	13
1254	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. 2015 , 24, 673-87	7
1253	Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. 2015 , 26, 888-894	84

1252	Brain metastases: an overview. 2015 , 4, 37-46		24
1251	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. 2015 , 88, 63-9		60
1250	Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations. 2015 , 32, 40		16
1249	Interstitial lung disease arising from erlotinib treatment in a Caucasian patient. 2015 , 16, e1-3		7
1248	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. 2015 , 16, 280-96		150
1247	Innovative Clinical Trials: The LUNG-MAP Study. 2015 , 97, 488-91		43
1246	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. 2015 , 33, 1881-8		454
1245	EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer. 2015 , 32, 420		3
1244	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. 2015 , 42, 634-43		14
1243	Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. 2015 , 16, 252-61		23
1242	Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study. 2015 , 98, 113-8		7
1241	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). 2015 , 87, 148-54		14
1240	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. 2015 , 87, 148-54		59
1239	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. 2015 , 121, E1-6		47
1238	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2015 , 16, 141-51	21,7	1081
1237	Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. 2015 , 87, 311-7		48
1236	Adaptive stress signaling in targeted cancer therapy resistance. 2015 , 34, 5599-606		43
1235	The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. 2015 , 20, 207-15		39

1234	What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. 2015 , 11, 153-67	20
1233	The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). 2015 , 36, 2491-9	7
1232	Brèves de l'ASCO. 2015 , 17, 57-60	
1231	Nit-picking around second line in EGFRwt NSCLC: just an academic effort. 2015 , 26, 448-50	
1230	Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?. 2015 , 123, 289-97	1
1229	Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. 2015 , 88, 108-11	243
1228	First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. 2015 , 16, 465-72	19
1227	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. 2015 , 21, 3631-9	183
1226	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. 2015 , 11, 421-9	7
1225	EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. 2015 , 75, 197-206	19
1224	Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. 2015 , 20, 659-67	0
1223	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. 2015 , 17, 103-12	21
1222	Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1 α in EGFR-mutated lung cancer in vitro and in vivo. 2015 , 17, 190-200	44
1221	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 2015 , 8, 461-77	26
1220	Advances in target therapy in lung cancer. 2015 , 24, 23-9	19
1219	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. 2015 , 112, 9990-5	24
1218	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. 2015 , 33, 2563-77	599
1217	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. 2015 , 21, 5305-13	126

1216	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. 2015 , 95, 306-17	19
1215	Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. 2015 , 89, 337-42	33
1214	Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. 2015 , 16, 1149-60	11
1213	[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]. 2015 , 102, 749-57	3
1212	Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. 2015 , 89, 301-5	9
1211	C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant. 2015 , 6, 1693-1697	20
1210	The complexities in system building strategies âThe case of personalized cancer medicines in England. 2015 , 98, 47-59	24
1209	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. 2015 , 94, 213-27	42
1208	Relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma. 2015 , 8, 249-52	2
1207	EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. 2015 , 24, 1254-61	32
1206	Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. 2015 , 16, 1434-7	5
1205	Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR. 2015 , 60, 141-50	15
1204	Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. 2015 , 89, 268-73	19
1203	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. 2015 , 33, 2472-80	76
1202	High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. 2015 , 36, 9215-22	14
1201	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). 2015 , 26, 1877-1883	308
1200	A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer. 2015 , 33, 241-5	3
1199	Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor. 2015 , 73, 799-804	1

1198	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. 2015 , 89, 280-6	13
1197	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. 2015 , 26, 1415-21	129
1196	EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. 2015 , 112, E3855-63	67
1195	Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. 2015 , 22, e183-215	50
1194	Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. 2015 , 76, 307-15	12
1193	EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. 2015 , 32, 205	20
1192	Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?. 2014 , 16, 747-57	25
1191	Biomarker testing in non-small cell lung cancer: a clinician's perspective. 2015 , 139, 448-50	5
1190	Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. 2015 , 24, 1101-9	28
1189	Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. 2015 , 75, 1335-48	77
1188	A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. 2015 , 51, 1904-10	14
1187	Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. 2015 , 29, 167-83	48
1186	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. 2015 , 90, 65-70	36
1185	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. 2015 , 26, 1883-1889	480
1184	Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling. 2015 , 96, 274-307	7
1183	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. 2015 , 21, 3196-203	341
1182	Emerging treatment for advanced lung cancer with EGFR mutation. 2015 , 20, 597-612	17
1181	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 990-8	21.7 291

1180	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. 2015 , 45, 569-75	7
1179	Chemotherapy for lung cancer: still alive!. 2015 , 45, 609-10	1
1178	Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. 2015 , 33, 1215-28	21
1177	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. 2015 , 75, 2489-500	206
1176	Management of egfr tki-induced dermatologic adverse events. 2015 , 22, 123-32	50
1175	Biomarkers in lung adenocarcinoma: a decade of progress. 2015 , 139, 469-80	46
1174	Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. 2015 , 72, 686	
1173	Actualizaci3n de las recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n avanzado de c3lula no peque~a. Consenso Nacional de la Sociedad Espa~ola de Anatom3a Patol3gica y de la Sociedad Espa~ola de Oncolog3a M3dica. 2015 , 48, 80-89	1
1172	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2015 , 33, 1666-73	84
1171	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. 2015 , 88, 74-9	127
1170	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. 2015 , 5, 475-87	378
1169	Overcoming resistance to targeted therapy for lung cancer. 2015 , 372, 1760-1	18
1168	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. 2015 , 20, 400-10	89
1167	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015 , 372, 1689-99	1447
1166	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. 2015 , 6, 224-6	0
1165	Rociletinib in EGFR-mutated non-small-cell lung cancer. 2015 , 372, 1700-9	524
1164	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. 2015 , 121, 2570-7	35
1163	Disease flare after gefitinib discontinuation. 2015 , 53, 68-72	7

1162 Traitements ciblés et immunothérapie : quel apport en pratique ?. **2015**, 7, 51-62

1161 Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility. **2015**, 87, 296-302 1

1160 [Second generation ALK inhibitors in non-small cell lung cancer: systemic review]. **2015**, 102, 381-9 4

1159 Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. **2015**, 16, 325-33 55

1158 Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. **2015**, 27, 36-48 7

1157 Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. **2015**, 88, 16-23 23

1156 Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. **2015**, 15, 465-75 12

1155 Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. **2015**, 33, 1958-65 211

1154 MET: a new promising biomarker in non-small-cell lung carcinoma. **2015**, 16, 631-47 20

1153 [Molecular diagnostics of non-small cell lung cancer: New markers and technologies]. **2015**, 36, 154-63 3

1152 The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. **2015**, 141, 61-8 30

1151 Targeting oncogenic drivers in lung cancer: celebrating a decade of progress. **2015**, 8, 81-83 1

1150 Androgen pathway manipulation and survival in patients with lung cancer. **2015**, 6, 120-7 18

1149 Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. **2015**, 36, 861-9 7

1148 CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients. **2015**, 36, 5943-51 16

1147 Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. **2015**, 39, 291-7 32

1146 EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib. **2015**, 16, 85 23

1145 The epidermal growth factor receptor (EGFR) in lung cancer. **2015**, 3, 1 26

1144	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. 2015 , 41, 401-11	33
1143	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. 2015 , 14, 97-110	5
1142	Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. 2015 , 11, 1259-74	10
1141	Addressing the unmet need in lung cancer: The potential of immuno-oncology. 2015 , 41, 465-75	25
1140	Refining the treatment of NSCLC according to histological and molecular subtypes. 2015 , 12, 511-26	189
1139	Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. 2015 , 21, 642-51	69
1138	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. 2015 , 1, 149-57	193
1137	CT-Guided Percutaneous Transthoracic Needle Biopsies Using 10G Large-Core Needles: Initial Experience. 2015 , 38, 1603-10	10
1136	Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. 2015 , 34, 173-82	6
1135	Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells. 2015 , 209, 327-36	34
1134	Biomarkers as Prognostic, Predictive, and Surrogate Endpoints. 2015 , 31-41	1
1133	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. 2015 , 26, 1830-1837	37
1132	Emerging paradigms in targeted treatments for Asian patients with NSCLC. 2015 , 16, 1167-76	15
1131	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. 2015 , 9, 255-68	21
1130	Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. 2015 , 121, 2078-82	12
1129	Caractérisation de populations tumorales dans les cancers bronchiques non ^petites cellules en TEP au FDG en fonction de critères anatomopathologiques et génétiques. 2015 , 39, 165-172	
1128	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. 2015 , 17, 265-72	145
1127	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. 2015 , 16, e25-35	78

1126	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015 , 33, 992-9		266
1125	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. 2015 , 33, 1000-7		177
1124	Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. 2015 , 11, 385-97		22
1123	Lâbfatinib, un nouveau mðdicament dans le cancer bronchique. 2015 , 54, 42-45		
1122	FGFR as potential target in the treatment of squamous non small cell lung cancer. 2015 , 41, 527-39		46
1121	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. 2015 , 21, 3552-60		166
1120	Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. 2015 , 21, 3529-40		35
1119	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. 2015 , 10, S1-63		102
1118	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology, The</i> , 2015 , 16, e165-72	21.7	477
1117	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. 2015 , 10, 665-72		22
1116	Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. 2015 , 10, 586-94		31
1115	High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer. 2015 , 94, e540		12
1114	Perception of lung cancer among the general population and comparison with other cancers. 2015 , 10, 420-5		21
1113	EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. 2015 , 10, 438-45		115
1112	Inhibition of ßCatenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. 2015 , 10, 93-101		34
1111	Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. 2015 , 5, 4		24
1110	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. 2015 , 10, 156-63		195
1109	Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. 2015 , 10, 486-91		82

1108	Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. 2015 , 26, 456-63	4
1107	Organoid development in cancer genome discovery. 2015 , 30, 42-8	40
1106	Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. 2015 , 26, 565-72	44
1105	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2015 , 27, 94-101	102
1104	Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. 2015 , 28, 124-33	21
1103	Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. 2015 , 11, 1245-57	44
1102	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). 2015 , 20, 370-8	92
1101	Management of EGFR mutated nonsmall cell lung carcinoma patients. 2015 , 45, 1132-41	25
1100	Lung cancer diagnosis in the emergency department. 2015 , 45, 867-8	3
1099	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. 2015 , 15, 1327-36	9
1098	Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. 2015 , 15, 1427-40	32
1097	Targeted therapy in cancer. 2015 , 76, 1113-32	89
1096	Predictive biomarkers in precision medicine and drug development against lung cancer. 2015 , 34, 295-309	29
1095	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2015 , 16, e447-e459	21.7 260
1094	How to develop novel treatments for EGFR-mutant lung cancer. 2015 , 11, 2375-8	4
1093	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. 2015 , 7, 263-73	38
1092	Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas. 2015 , 46, 1935-44	10
1091	The development of precision medicine in clinical practice. 2015 , 4, 69	7

1090	Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. 2015 , 90, 307-13	16
1089	Alopecia in patients treated with molecularly targeted anticancer therapies. 2015 , 26, 2496-502	30
1088	Overcoming Resistance to Targeted Therapies in Cancer. 2015 , 42, 896-908	31
1087	Current challenges of lung cancer care in an aging population. 2015 , 15, 1419-29	8
1086	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. 2015 , 192, 539-544	73
1085	Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. 2015 , 90, 472-6	11
1084	Resistance to EGFR-targeted therapy by Ets-1 inactivation. 2015 , 14, 3211-2	3
1083	AKT inactivation causes persistent drug tolerance to EGFR inhibitors. 2015 , 102, 132-7	22
1082	[Treatment of advanced non-small-cell lung cancer with driver mutations]. 2015 , 140, 323-8	1
1081	Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIa. 2015 , 24, 340-55	20
1080	Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. 2015 , 15, 287-9	5
1079	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. 2015 , 16, 1135-48	26
1078	Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors. 2015 , 11, 2329-42	13
1077	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. 2015 , 90, 1-7	10
1076	[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC]. 2015 , 102, S27-33	0
1075	The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes. 2015 , 5, 217-228	
1074	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. 2015 , 90, 534-41	32
1073	Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. 2015 , 4, 1621-32	32

1072	A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines. 2015 , 144, 1287-95	26
1071	Pharmacogenomics in the treatment of lung cancer: an update. 2015 , 16, 1751-60	4
1070	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. 2015 , 107,	106
1069	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. 2015 , 32, 907-16	8
1068	Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis. 2015 , 104, 129-36	18
1067	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. 2015 , 113, 1519-28	70
1066	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). 2015 , 26, 1547-73	451
1065	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. 2015 , 11, 489-500	17
1064	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. 2015 , 24, 1493-500	81
1063	Considerations on the management of EGF receptor-TKIs for brain metastases in EGFR-mutant lung carcinoma patients. 2015 , 4, 43-49	1
1062	[Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]. 2015 , 102, S93-5	
1061	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. 2015 , 26, 2073-8	219
1060	The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer. 2015 , 9, 241-4	17
1059	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. 2015 , 11, 267-77	12
1058	Lung cancer: Biology and treatment options. 2015 , 1856, 189-210	322
1057	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. 2015 , 6, e1850	31
1056	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. 2015 , 373, 726-36	1172
1055	The impact of the Cancer Genome Atlas on lung cancer. 2015 , 166, 568-85	56

1054	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2015 , 33, 3488-515	363
1053	Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. 2015 , 11, 2525-40	17
1052	Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. 2015 , 18, 774-82	47
1051	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-III A Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. 2015 , 33, 4007-14	238
1050	The future of immunotherapy in the treatment of lung cancer. 2015 , 4, 57-73	2
1049	Emergency medical genomes: a breakthrough application of precision medicine. 2015 , 7, 82	18
1048	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. 2015 , 17, 1483-91	7
1047	Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. 2015 , 89, 287-93	25
1046	EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. 2015 , 5, 1155-63	63
1045	EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. 2015 , 76, 835-41	35
1044	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. 2015 , 90, 261-6	4
1043	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. 2015 , 369, 97-102	71
1042	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. 2015 , 15, 1553-66	16
1041	Casting a wide net: HSP90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC. 2015 , 4, 5-8	
1040	Role of circulating-tumor DNA analysis in non-small cell lung cancer. 2015 , 90, 128-34	72
1039	Influencing cancer treatment. <i>Lancet Oncology, The</i> , 2015 , 16, 1591-3	21.7 2
1038	PTEN and PI3K/AKT in non-small-cell lung cancer. 2015 , 16, 1843-62	140
1037	Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials. 2015 , 16, 173-182.e4	18

1036	Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations. 2015 , 16, e97-9	2
1035	Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon's triamcinolone without erlotinib cessation. 2015 , 50, e66-7	2
1034	Secondary localized corneal amyloidosis caused by lower eyelid epiblepharon. 2015 , 50, e67-9	2
1033	A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?. 2015 , 16, e173-81	20
1032	Microenvironmental regulation of therapeutic response in cancer. 2015 , 25, 198-213	427
1031	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. 2015 , 17, 296-302	57
1030	Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials. 2015 , 31, 25-33	8
1029	Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. 2015 , 27, 40-51	38
1028	Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. 2015 , 16, 60-6	10
1027	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. 2015 , 14, 542-52	26
1026	Pharmacogenomic biomarkers for personalized cancer treatment. 2015 , 277, 201-217	38
1025	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 2015 ,	4
1024	The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. 2015 , 123, 108-15	45
1023	[Assessment of a tool for decision making in case of worsening condition of cancer patients]. 2015 , 32, 66-72	2
1022	Management of Bladder Cancer. 2015 ,	1
1021	[Targeted therapies in non-small cell lung cancer in 2014]. 2015 , 32, 182-92	8
1020	Pharmacogenomics and the resulting impact on psoriasis therapies. 2015 , 33, 149-60	8
1019	Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. 2015 , 11, 4-14	12

1018	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. 2015 , 112, 95-102	407
1017	Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. 2015 , 47, 550-5	19
1016	Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. 2015 , 16, 33-9	71
1015	New Therapeutic Strategies in Lung Cancers. 2015 ,	0
1014	Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?. 2014 , 4, 5996	7
1013	Personalised cancer medicine. 2015 , 137, 262-6	186
1012	Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. 2016 , 129, 332-40	17
1011	Analysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population. 2016 , 15, 1637	1
1010	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. 2016 , 3, 9-15	1
1009	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. 2016 , 7, 69450-69465	42
1008	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. 2016 , 7, 1066-75	120
1007	Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. 2016 , 7, 91-97	7
1006	The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis. 2016 , 9, 171-81	20
1005	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. 2016 , 9, 929-35	10
1004	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. 2016 , 7, 633-49	22
1003	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). 2016 , 7, 58492-58499	61
1002	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. 2016 , 7, 66880-66891	48
1001	Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. 2016 , 7, 71782-71789	16

1000	Precision medicine in lung cancer: the battle continues. 2016 , 8, 2991-2993	3
999	Targeted therapies and immunotherapy in non-small-cell lung cancer. 2016 , 10, 648	20
998	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
997	Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. 2016 , 7, 61755-61763	25
996	Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation. 2016 , 5, 265-268	10
995	Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. 2017 , 9, 31-38	13
994	Lung cancer in Brazil: epidemiology and treatment challenges. 2016 , 7, 141-148	10
993	Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/ β -catenin signaling. 2016 , 7, 31413-28	76
992	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. 2016 , 79, 248-256	27
991	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. 2016 , 1,	52
990	Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer. 2016 , 22, 1194-203	8
989	Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. 2016 , 7, 86313-86325	27
988	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. 2016 , 5, 532-537	5
987	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. 2016 , 7, 3884-96	25
986	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. 2016 , 5, 563-578	28
985	Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. 2016 , 7, 81598-81610	28
984	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. 2016 , 8, E217-20	5
983	B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up. 2016 , 5, 367-9	6

982	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. 2016 , 5, 446-9	5
981	Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. 2016 , 5, 401-12	38
980	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. 2016 , 5, 628-636	12
979	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. 2016 , 5, 727-730	11
978	Non-Small-Cell Lung Cancer Treatment. 2016 , 62, 7-12	1
977	Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. 2016 , 8, E200-3	7
976	Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit. 2016 , 8, E1455-E1461	5
975	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. 2016 , 8, E1517-E1519	1
974	Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?. 2016 , 5, 373-6	7
973	Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis. 2016 , 5, 202-7	18
972	Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. 2016 , 5, 331-7	39
971	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. 2016 , 8, 173-85	26
970	Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations. 2016 , 8, E1293-E1295	1
969	The feasibility of molecular testing on cell blocks created from brush tip washings in the assessment of peripheral lung lesions. 2016 , 8, 2551-2555	11
968	Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR. 2016 , 7, 16273-81	9
967	Approach to biomarker testing: perspectives from various specialties. 2016 , 23, 178-83	4
966	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2016 , 5, 172-82	53
965	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. 2016 , 7, 20810-24	63

964	Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?. 2016 , 5, 466-482	50
963	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. 2016 , 5, 525-531	13
962	Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. 2016 , 7, 28748-60	73
961	Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. 2016 , 2016, 3494608	24
960	EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method. 2016 , 2016, 5297329	23
959	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. 2016 , 17,	17
958	Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. 2016 , 7, 71013-71035	52
957	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. 2016 , 9, 1291-302	7
956	Valuing the benefits of new anticancer drugs. 2016 , 204, 403-5	
955	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. 2016 , 9, 5461-73	32
954	The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. 2016 , 7, 78985-78993	267
953	EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). 2016 , 8, 11-20	11
952	A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib. 2016 , 9, 223-7	3
951	Epidemiological profile and prognostic factors in patients with lung cancer. 2016 , 62, 428-33	6
950	Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study. 2016 , 9, 4037-41	
949	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. 2016 , 6, 112	20
948	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. 2016 , 6, 165	4
947	Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer. 2016 , 17, 237	37

946	Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. 2016 , 17,	19
945	EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. 2016 , 17,	33
944	Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants. 2016 , 21,	9
943	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. 2016 , 17, 105	9
942	Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. 2016 , 11, e0154293	9
941	Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China. 2016 , 11, e0151846	10
940	Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. 2016 , 11, e0160148	8
939	Oligometastatic non-small-cell lung cancer: current treatment strategies. 2016 , 7, 129-140	9
938	Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. 2016 , 9, 1579-87	21
937	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. 2016 , 9, 3711-26	71
936	Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis. 2016 , 9, 1135-43	16
935	Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. 2016 , 10, 3867-3872	28
934	Overcoming Resistance to EGFR Inhibitors in NSCLC. 2016 , 11, 99-105	10
933	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. 2016 , 4, 215	6
932	The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations. 2016 , 56, 331-336	
931	Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. 2016 , 7, 49948-49960	75
930	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. 2016 , 7, 51922-51933	71
929	Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives. 2016 , 28, 150-8	5

928	Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. 2016 , 39, 556-562	2
927	Spécificité de la prise en charge du CBNPC chez les sujets âgés. 2016 , 18, 401-408	1
926	Les cancers du poumon avec une mutation oncogénique : une prise en charge de plus en plus spécifique. 2016 , 18, 371-375	1
925	The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. 2016 , 39, 126-31	11
924	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. 2016 , 101, 1-8	99
923	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2016 , 28, 115-21	18
922	Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2016 , 34, 3233-4	
921	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. 2016 , 138, 2549-61	119
920	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. 2016 , 17, 1693-701	5
919	Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas. 2016 , 14, 1132-8	8
918	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 2016 , 34, 2980-7	338
917	Increased FLI-1 Expression is Associated With Poor Prognosis in Non-Small Cell Lung Cancers. 2016 , 24, 556-61	3
916	High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. 2016 , 55, 30-44	52
915	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2016 , 10, 152-6	6
914	Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal. 2016 , 100, 1833-9	19
913	Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. 2016 , 17, 507-516	36
912	[Molecular epidemiology of the lung cancer]. 2016 , 33, 675-681	
911	Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. 2016 , 30, 1150-1154	28

910	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. 2016 , CD010383	98
909	The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. 2016 , 61, 179-89	5
908	The development of potential targets in the treatment of non-small cell lung cancer. 2016 , 11, 225-231	
907	Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episenitization. 2016 , 9, 62-7	15
906	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. 2016 , 6, 37997	23
905	Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. 2016 , 55, 3105-3111	10
904	The cost and value of cancer drugs - are new innovations outpacing our ability to pay?. 2016 , 5, 40	12
903	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. 2016 , 16, 425-33	13
902	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. 2016 , 128, 11069-11073	4
901	Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. 2016 , 11, 68-77	7
900	A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. 2016 , 16, 19-29	5
899	A Comprehensive Overview of Mouse Models in Oncology. 2016 , 79-107	
898	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. 2016 , 23, 86	35
897	Indications de ranimation en oncologie thoracique. 2016 , 8, 506-514	
896	Les cancers bronchiques non ^petites cellules EGFR-mut\$. 2016 , 8, 373-381	
895	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. 2016 , 15, 837-51	10
894	Immune checkpoint inhibitors in lung cancer: past, present and future. 2016 , 12, 1151-63	24
893	Inequalities in lung cancer: a world of EGFR. 2016 , 47, 1502-9	14

892	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016,	2
891	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. 2016, 34, 3248-57	102
890	Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update. 2016, 18, 32	10
889	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. 2016, 11, 946-63	145
888	Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?. 2016, 11, 79-84	37
887	MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessing the efficacy of their combination with mNSCLC EGFR Mut. 2016, 22, 227-3	
886	Integrin α -mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. 2016, 11, 535-542	16
885	S768I Mutation in EGFR in Patients with Lung Cancer. 2016, 11, 1798-801	41
884	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2016, 17, 461-465	27
883	Specialty pharmacy services for patients receiving oral medications for solid tumors. 2016, 73, 775-96	10
882	Safety of gefitinib in non-small cell lung cancer treatment. 2016, 15, 993-1000	5
881	Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor. 2016, 77, 1019-29	5
880	New oncogenes drivers in lung cancer—New therapeutic targets. 2016, 5, 49-56	
879	Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. 2016, 94, 68-73	55
878	Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. 2016, 10, 256-64	12
877	Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?. 2016, 34, 774-6	
876	Risk factors and management of oligometastatic non-small cell lung cancer. 2016, 10, 338-48	15
875	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology, The,</i> 2016, 17, 577-89	21.7 691

874	The Conundrum of Genetic "Drivers" in Benign Conditions. 2016 , 108,		89
873	A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma. 2016 , 457, 106-11		25
872	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. 2016 , 95, 663-72		22
871	EGFR mutation status on brain metastases from non-small cell lung cancer. 2016 , 96, 101-7		66
870	Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples. 2016 , 20, 241-53		1
869	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. 2016 , 9, 34		189
868	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 642-50	21.7	269
867	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. 2016 , 101, 32-9		13
866	Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. 2016 , 90, 289-98		7
865	Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China. 2016 , 4, 749-755		10
864	EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. 2016 , 11, 3546-3550		12
863	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. 2016 , 12, 2219-31		33
862	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. 2016 , 76, 831-40		11
861	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. 2016 , 16, 737-49		20
860	The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. 2016 , 22, 755-61		2
859	Tyrosine kinase inhibitors as first-line treatment in NSCLC. <i>Lancet Oncology, The</i> , 2016 , 17, 541-3	21.7	2
858	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach. 2016 , 94, 20-32		15
857	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. 2016 , 6, 601-11		65

856	Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation. 2016 , 22, 763-8	18
855	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. 2016 , 100, 77-84	70
854	Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. 2016 , 99, 1-3	11
853	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. 2016 , 96, 406-413	57
852	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. 2016 , 27, 2103-2110	128
851	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. 2016 , 115, 784-8	10
850	A primer and probe set for detecting multiple types of EGFR exon 19 deletions. 2016 , 513, 61-67	1
849	Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. 2016 , 9, 41-43	4
848	Global Conservation of Protein Status between Cell Lines and Xenografts. 2016 , 9, 313-21	9
847	Resisting Resistance: Targeted Therapies in Lung Cancer. 2016 , 2, 350-364	94
846	[Evidence on afatinib in patients progressing on a first-line treatment]. 2016 , 146 Suppl 1, 19-24	
845	[Osimertinib (Tagrisso): Activity, indication and modality of use in non-small cell lung cancer]. 2016 , 103, 815-821	0
844	[Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?]. 2016 , 33, 817-823	1
843	[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma]. 2016 , 146 Suppl 1, 2-6	3
842	Rflexion autour de la médecine de précision: exemple de la RCP moléculaire en cancérologie. 2016 , 2, 402-406	
841	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. 2016 , 10, 1229-1241	9
840	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. 2016 , 78, 941-947	5
839	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. 2016 , 17, 2253-2266	22

838	Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response. 2016 , 7, 639-647	5
837	A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. 2016 , 68, 1140-1148	7
836	Brain Metastasis: Clinical Implications of Branched Evolution. 2016 , 2, 332-337	15
835	[Toxicity associated with EGFR inhibition: review and key aspects in the management of afatinib]. 2016 , 146 Suppl 1, 30-5	1
834	Metastatic Lung Cancer: Emerging Therapeutic Strategies. 2016 , 37, 736-749	1
833	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. 2016 , 37, 771-782	8
832	EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. 2016 , 37, 887-903	65
831	Divide and Conquer to Treat Lung Cancer. 2016 , 375, 1892-1893	12
830	Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan. 2016 , 46, 1135-1142	1
829	Emerging from their burrow: Hedgehog pathway inhibitors for cancer. 2016 , 25, 1153-66	18
828	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). 2016 , 9, 48-55	4
827	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. 2016 , 11, 1682-9	127
826	Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials. 2016 , 32, 1927-1934	
825	Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review. 2016 , 99, 76-8	9
824	Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. 2016 , 107, 1134-40	61
823	Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. 2016 , 55, 10909-12	38
822	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. 2016 , 34, 3258-66	107
821	Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. 2016 , 78, 427-32	17

820	[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy]. 2016 , 70, 514-21	0
819	Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. 2016 , 5, 1055-65	60
818	Chemotherapy remains an essential element of personalized care for persons with lung cancers. 2016 , 27, 1829-35	52
817	MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation. 2016 , 7, 279-87	5
816	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. 2016 , 107, 461-8	29
815	High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. 2016 , 7, 100-10	9
814	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. 2016 , 107, 1179-86	210
813	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. 2016 , 25, 1441-9	14
812	The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. 2016 , 11, 1615-26	57
811	Mass spectrometry-based secretome analysis of non-small cell lung cancer cell lines. 2016 , 16, 2801-2814	11
810	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. 2016 , 1, e000060	229
809	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. 2016 , 11, 2066-2081	40
808	Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. 2016 , 7, 663-669	17
807	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. 2016 , 388, 1002-11	113
806	New and emerging targeted treatments in advanced non-small-cell lung cancer. 2016 , 388, 1012-24	299
805	Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer. 2016 , 101, 9-10	10
804	Management of Lung Cancer in the Elderly. 2016 , 170, 251-84	8
803	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. 2016 , 11, 1387-96	6

802	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. 2016 , 12, 2741-2753	8
801	Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. 2016 , 11, 1962-1969	128
800	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. 2016 , 122, 3456-3463	11
799	Precision, accuracy, and resolution-Dose selection of oral anticancer agents. 2016 , 122, 3424-3427	1
798	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. 2016 , 17, 54	13
797	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. 2016 , 469, 489-503	146
796	The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. 2016 , 5, 1244	10
795	Targeted Therapies for Lung Cancer. 2016 , 170, 165-82	10
794	Resistance to Therapy. 2016 , 170, 183-202	6
793	Stratified Treatment in Lung Cancer. 2016 , 39, 760-766	12
792	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. 2016 , 115, 1504-1512	38
791	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. 2016 , 21, 1326-1336	25
790	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. 2016 , 9, 1283-1288	1
789	Novel immunotherapy in the treatment of advanced non-small cell lung cancer. 2016 , 9, 1571-1581	18
788	Crizotinib: from discovery to accelerated development to front-line treatment. 2016 , 27 Suppl 3, iii35-iii41	27
787	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. 2016 , 21, 964-73	31
786	The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. 2016 , 49, 1360-8	164
785	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. 2016 , 9, 86	31

784	Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. 2016 , 49, 1576-88		17
783	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. 2016 , 8, 460-473		26
782	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. 2016 , 33, 97		30
781	Management of non-small cell lung cancer in the era of personalized medicine. 2016 , 78, 173-179		18
780	Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. 2016 , 34, 3361-2		16
779	Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. 2016 , 52, 2-62		11
778	Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. 2016 , 46, 928-934		8
777	Recommendations of the Spanish Society of Pneumology and Thoracic Surgery on the diagnosis and treatment of non-small-cell lung cancer. 2016 , 52 Suppl 1, 2-62		13
776	[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation]. 2016 , 146 Suppl 1, 12-8		
775	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 1643-1652	21.7	412
774	The prospect of patritumab for treating non-small cell lung cancer. 2016 , 16, 1549-1555		3
773	Profile of the theascreen [®] EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. 2016 , 16, 1251-1257		13
772	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 2016 , 1, e000088		69
771	Targeted therapy and elderly people: A review. 2016 , 69, 199-215		22
770	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. 2016 , 1, e000066		14
769	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. 2016 , 1, e000081		5
768	Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. 2016 , 6, 26241		38
767	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. 2016 , 16, 864		31

766	Cancer Drug Discovery. 2016,		5
765	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. 2016, 7, 17-27		
764	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. 2016, 102, 122-134		98
763	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. 2016, 9, ra33		41
762	A genetic basis for the variation in the vulnerability of cancer to DNA damage. 2016, 7, 11428		95
761	Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. 2016, 6, 33505		37
760	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 1661-1671	21.7	86
759	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. 2016, 6, 36371		5
758	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. 2016, 6, 36458		60
757	Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib. 2016, 7, 681-683		4
756	Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. 2016, 10, 549-565		32
755	The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database. 2016, 102, 96-100		1
754	Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. 2016, 7, 543-548		7
753	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. 2016, 21, 1450-1460		70
752	Resistance to Tyrosine Kinase Inhibitors. 2016,		1
751	A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations. 2016, 23, 58		9
750	Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. 2016, 6, 31636		3
749	Circulating tumor DNA detection in lung cancer patients before and after surgery. 2016, 6, 33519		59

748	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. 2016 , 7, 11815	409
747	Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients. 2016 , 6, 23368	14
746	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. 2016 , 6, 20913	151
745	Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy. 2016 , 2016, 1268-1271	12
744	Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib. 2016 , 5, 14-18	6
743	SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. 2016 , 39, 681-686	3
742	A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds. 2016 , e53885	16
741	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v1-v27	590
740	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. 2016 , 91 Suppl 1, 26-34	10
739	Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. 2016 , 31, 238-42	1
738	A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma. 2016 , 38, 657-662	8
737	Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study. 2016 , 95, e3998	18
736	EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. 2016 , 95, e5601	9
735	Best Practices in Treatment Selection for Patients With Advanced NSCLC. 2016 , 23, 2-14	5
734	Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. 2016 , 138, 1024-32	25
733	Mutations in Latinos From the United States and Latin America. 2016 , 2, 259-267	8
732	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. 2016 , 22, 6010-6020	84
731	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. 2016 , 14, 83	14

730	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. 2016 , 2, 1452-1459	190
729	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 984-993	498
728	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. 2016 , 11, 1293-1304	97
727	Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. 2016 , 17, 833-9	19
726	Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. 2016 , 16, 354	6
725	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. 2016 , 5, 45	12
724	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. 2016 , 5, 79-90	1
723	Necitumumab in squamous non-small-cell lung cancer: how to move forward?. 2016 , 27, 1374-6	
722	Clinicopathologic Features of Advanced Squamous NSCLC. 2016 , 11, 1411-22	57
721	Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology. 2016 , 18, 319-328	58
720	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. 2016 , 77, 1005-9	12
719	The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. 2016 , 18, 915-24	10
718	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. 2016 , 2, 1-18	2
717	Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials. 2016 , 17, 91-4	3
716	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. 2016 , 17, 474-482	14
715	Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. 2016 , 98, 1-8	16
714	Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. 2016 , 98, 84-90	4
713	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. 2016 , 8, 176-87	22

712	The 5000% case: a glimpse into the financial issue of lung cancer treatment. 2016 , 47, 1331-3	2
711	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. 2016 , 11, 1140-52	46
710	The use of biomarkers in the treatment of non-small cell lung cancer. 2016 , 1, 25-36	2
709	Targeted Therapy and Immunotherapy for Lung Cancer. 2016 , 25, 601-9	56
708	Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. 2016 , 16, 147	11
707	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. 2016 , 16, 210	25
706	Diagnostik des Lungenkarzinoms. 2016 , 13, 223-232	
705	Stratification in advanced non-small cell lung cancer: precision medicine in practice. 2016 , 1, 279-287	1
704	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. 2016 , 10, 485-91	8
703	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. 2016 , 34, 3375-82	605
702	Effect of renal function on pemetrexed-induced haematotoxicity. 2016 , 78, 183-9	6
701	EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review. 2016 , 212, 672-7	23
700	Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. 2016 , 27, 251-3	3
699	A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer. 2016 , 20, 424-31	25
698	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). 2016 , 46, 25-37	26
697	Pathology: Malignant and Interstitial Lung Diseases. 2016 , 225-250.e7	
696	Large-scale screening for somatic mutations in lung cancer. 2016 , 387, 1354-1356	67
695	A Phase I Trial of Temezirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer. 2016 , 61, 144-7	13

694	Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. 2016 , 25, 359-65	1
693	EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. 2016 , 17, 320-7	26
692	Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. 2016 , 17, 193-203	1
691	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. 2016 , 33, 16	15
690	Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. 2016 , 127, 525-33	9
689	Targeted therapy in cancer. 2016 , 44, 34-38	18
688	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. 2016 , 11, 167-74	15
687	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. 2016 , 34, 91-101	107
686	Drug-diagnostic co-development: challenges and issues. 2016 , 16, 187-204	3
685	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. 2016 , 91, 36-40	29
684	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. 2016 , 10, 113-29	97
683	Implementation Science for Global Oncology: The Imperative to Evaluate the Safety and Efficacy of Cancer Care Delivery. 2016 , 34, 43-52	12
682	Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. 2016 , 12, 59-70	32
681	Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. 2016 , 72, 1-11	42
680	The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis. 2016 , 95, e2495	9
679	Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2016 , 39, 396-406	21
678	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. 2016 , 22, 1307-12	122
677	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. 2016 , 11, 801-7	16

676	Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer. 2016 , 194, 371-8	25
675	[Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma]. 2016 , 33, 751-756	1
674	2015 and human cancer: back to overall survival. 2016 , 12, 1751-4	
673	Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations. 2016 , 7, 24-31	2
672	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis. 2016 , 7, 406-14	18
671	Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer. 2016 , 12, 86-90	5
670	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. 2016 , 193, 1213-8	47
669	Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis. 2016 , 61, 41-50	8
668	Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. 2016 , 57, i58-i68	20
667	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. 2016 , 96, 87-92	53
666	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. 2016 , 93, 9-16	23
665	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. 2016 , 93, 59-68	87
664	Skin problems and EGFR-tyrosine kinase inhibitor. 2016 , 46, 291-8	59
663	Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. 2016 , 69, 440-7	13
662	Pharmacogenetics and pharmacogenomics as tools in cancer therapy. 2016 , 31, 25-34	18
661	Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. 2016 , 95, 673-9	64
660	Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer. 2016 , 23, 2115-22	5
659	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2016 , 17, 161-8	13

- 658 Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report. **2016**, 90, 176-7 4
- 657 Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. **2016**, 100, 107-16 76
- 656 Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature. **2016**, 11, 174-86 63
- 655 [Lung cancer and rheumatoid arthritis. An interdisciplinary challenge]. **2016**, 75, 47-53 2
- 654 [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. **2016**, 36, 63-72 3
- 653 [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]. **2016**, 103, 55-65 5
- 652 Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. **2016**, 12, 815-25 3
- 651 Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III. **2019**, 18, 6451-6458
- 650 Neurological Complications of Targeted Therapies. **2020**, 341-363
- 649 Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?. **2019**, 8, S633-S635
- 648 Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmaco-economic study. **2019**, 137, 505-511
- 647 High frequency of Exon 20 S768I EGFR mutation detected in malignant pleural effusions: a poor prognosticator of NSCLC?.
- 646 Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer. **2019**, 20, 3591-3596 1
- 645 Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
- 644 Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei.
- 643 Cancer in Older Adults. **2020**, 189-209
- 642 Empirical treatment with epithelial growth factor receptor tyrosine kinase inhibitor for neoplastic acute respiratory distress syndrome. **2020**, 86, 218-220
- 641 Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study. 1-1 0

- 640 Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
- 639 Developing Pathology Measures for the Quality Payment Program-Part I: A Quest for Meaningful Measures. **2020**, 144, 686-696 1
- 638 Role of imaging biomarkers in mutation-driven non-small cell lung cancer. **2020**, 11, 412-427 1
- 637 Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. **2020**, 96, 266-272 2
- 636 Recomendaciones de oncólogos que trabajan en el ISSSTE para el tratamiento sistémico del cáncer de pulmón avanzado 2020. **2020**, 2, 164-181
- 635 Implications of the success of EGFR-targeted therapy in advanced non-small cell lung cancer for its application to the adjuvant setting. **2020**, 12, 4553-4555
- 634 Quantification of [¹⁸F]afatinib using PET/CT in NSCLC patients: a feasibility study. **2020**, 10, 97 1
- 633 Use of adjuvant EGFR tyrosine kinase inhibitors in early stage -mutant non-small cell lung cancer: is the evidence strong enough?. **2020**, 12, 5042-5045 0
- 632 EBUS in optimizing non-small cell lung cancer diagnosis and treatment. **2021**, 94, 176-184 2
- 631 Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.. **2021**, 10, 4217-4231 0
- 630 Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.
- 629 Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. **2020**, 14, 1651-1662
- 628 Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. **2020**, 48, 300060520980205 2
- 627 OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. **2020**, 19, 119-125
- 626 Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma. **2020**, 15, e0240736
- 625 Aktuelle Entwicklungen in der personalisierten Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms âUpdate. **2021**, 16, 8-16
- 624 Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all. **2020**, 8, 1697
- 623 Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.. **2020**, 9, 7562-7571

622	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. 2020 , 9, 2599-2617	0
621	Respiratory Organ Aging and Cancer. 2020 , 215-244	
620	Targeted Therapies. 2020 , 1-13	
619	EGFR+ EGFR+ EGFR+ 2020 , 199-204	
618	Principles of Cancer Targeted Therapy in Older Adults. 2020 , 881-894	
617	Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.	
616	Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. 2020 , 46, e20180255	0
615	Targeting lung cancer using advanced drug delivery systems. 2020 , 493-516	1
614	Clinical Performance Evaluation Of The Idylla Egfr Mutation Test On Formalin-Fixed Paraffin-Embedded Tissue Of Non-Small Cell Lung Cancer.	
613	Clinical Performance Evaluation of the Idylla Egfr Mutation Test on Formalin-Fixed Paraffin-Embedded Tissue of Non-Small Cell Lung Cancer.	
612	Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.	
611	Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma. 2020 , 58, 1547-1555	1
610	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. 2021 , 1	2
609	Advances in systemic therapy for non-small cell lung cancer. 2021 , 375, n2363	7
608	A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. 2021 ,	1
607	Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.. 2021 , 119, 105469	1
606	The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status. 2021 , 8, 728575	0
605	A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer.. 2022 , 13, 312-323	3

604	High-resolution computed tomography findings independently predict epidermal growth factor receptor mutation status in ground-glass nodular lung adenocarcinoma. 2021 , 9, 9792-9803	
603	Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. 2021 , 162, 154-161	4
602	Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. 2021 , 26, 639-656	2
601	Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). 2021 , 159, 144-153	2
600	First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. 2021 , 159, 174-181	0
599	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. 2020 , 53, 140-148	
598	Sequencing Therapy for Patients With Lung Cancer. 2020 , 18, 945-948	
597	Cancer Drug Delivery. 52-95	
596	Molecular pathology. 95-118	1
595	Systemic treatment of elderly patients. 202-214	
594	Achievements in targeted therapies. 215-233	
593	Perspective of a pulmonologist: what might we expect and what do we need to know?. 261-273	
592	Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city. 2020 , 30, 463-472	1
591	Morphological and molecular genetic diagnosis of lung cancer: methods and problems. 2020 , 7, 51-62	2
590	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.	1
589	Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy. 2020 , 26, 548-554	0
588	Multi-state network meta-analysis of cause-specific survival data.	
587	Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors.	

586	Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in -Mutated Lung Cancer. 2020 , 1, 100085	3
585	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. 2021 , 80, 100795	0
584	EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. 2012 , 4, 219-20	8
583	A time to test, a time to treat. 2012 , 4, 223-5	1
582	Predicting resistance by selection of signaling pathways. 2014 , 3, 107-15	20
581	First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?. 2012 , 1, 219-23	4
580	Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. 2012 , 1, 96-8	9
579	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. 2012 , 4, 226-8	2
578	EURTAC first line therapy for non small cell lung carcinoma in epidermal growth factor receptor mutation positive patients: A choice between two TKIs. 2012 , 4, 221-2	1
577	RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. 2013 , 6, 1493-504	20
576	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. 2014 , 4, 411-35	96
575	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. 2014 , 11, 173-81	19
574	Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). 2014 , 6, 1489-98	2
573	Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. 2014 , 26, 705-10	2
572	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. 2015 , 3, 32	
571	The TORCH trial. 2012 , 1, 283-6	1
570	Expanding options for EGFR targeting in lung cancer. 2012 , 1, 287-8	2
569	Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. 2012 , 1, 224-6	

568	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. 2012 , 1, 227-9	
567	Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?. 2012 , 1, 152-4	1
566	Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. 2012 , 1, 129-44	2
565	Personalized maintenance therapy in advanced non-small cell lung cancer. 2013 , 2, 452-6	
564	Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?. 2013 , 2, 55-7	
563	MET inhibition in lung cancer. 2013 , 2, 23-39	11
562	Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study. 2013 , 2, 58-61	1
561	10(th) Congress on Lung Cancer-updates on clinical trials: goal. 2014 , 3, 66-9	1
560	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. 2013 , 2, 411-4	1
559	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. 2015 , 7, 217-9	
558	Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. 2015 , 8, 2888-98	7
557	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. 2015 , 12, 126-39	19
556	Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. 2015 , 8, 5577-83	4
555	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. 2015 , 7, 1126-39	19
554	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. 2015 , 5, 2229-40	5
553	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. 2015 , 8, 10330-9	16
552	Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. 2015 , 8, 9010-20	8
551	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. 2015 , 4, 649-52	2

550	EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). 2015 , 5, 2892-911	243
549	Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. 2015 , 8, 13136-45	17
548	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. 2015 , 4, 704-12	7
547	Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. 2016 , 4, 50	8
546	Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis. 2016 , 8, 98-115	5
545	Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2016 , 8, 68-78	6
544	Afatinib in Non-Small Cell Lung Cancer. 2015 , 6, 448-55	5
543	Methylation of kruppel-like factor 2 (KLF2) associates with its expression and non-small cell lung cancer progression. 2017 , 9, 2024-2037	13
542	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. 2017 , 34, 405-408	0
541	Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy. 2017 , 17, 362-378	8
540	Molecular Targets in Non-Small Cell Lung Cancer. 2017 , 17, 388-392	14
539	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. 2016 , 7, 723-735	4
538	[Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance]. 2016 , 19, 600-6	
537	[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment?(2016 version)]. 2016 , 19, 489-94	6
536	[Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System ?Metastases from Non-small Cell Lung Cancer]. 2016 , 19, 496-500	
535	[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]. 2016 , 19, 550-8	2
534	[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. 2017 , 20, 720-726	1
533	[Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features]. 2018 , 21, 241-250	1

532	[Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer ?in Different Genotypes]. 2017 , 20, 741-750	1
531	[New Progress in the Relationship between Immune Cells, PD-1 ?in Tumor Microenvironment and the Efficacy of EGFR-TKIs]. 2017 , 20, 775-780	
530	[Efficacy and Toxicity of Metronomic Oral Vinorelbine in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments]. 2017 , 20, 737-740	2
529	[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer]. 2017 , 20, 61-65	1
528	[Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma]. 2018 , 21, 303-309	1
527	[Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma]. 2017 , 20, 589-597	
526	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. 2017 , 20, 617-622	3
525	[Current Status and Progress in Molecular Imaging of Non-small Cell Lung ?Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and ?Treatment Tolerance Prediction]. 2017 , 20, 852-856	
524	[Driven Gene in Patients with Lung Squamous Cell Carcinoma: ?Analysis of Clinicopathologic Characteristics and Prognosis]. 2016 , 19, 648-652	1
523	[Primary Application of Radiofrequency Ablation after Locally Progression of?EGFR-TKIs in Non-small Cell Lung Cancer]. 2016 , 19, 859-863	1
522	[Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted ?Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors]. 2017 , 20, 278-286	1
521	[Clinical Analysis of Icotinib on Beneficiary of ?Advanced Non-small Cell Lung Cancer with EGFR Common Mutation]. 2016 , 19, 200-6	3
520	[Nimotuzumab significantly enhances chemosensitivity of?PC9 human lung adenocarcinoma cells to paclitaxel in vitro]. 2015 , 18, 98-103	0
519	[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. 2015 , 18, 110-6	
518	[Treatment of patients with ALK gene rearranged non-small cell lung cancer ?after resistance to crizotinib]. 2015 , 18, 69-74	
517	[Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. 2015 , 18, 146-54	0
516	[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]. 2014 , 17, 321-6	1
515	[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature]. 2014 , 17, 342-6	

514	[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations]. 2014 , 17, 155-62	2
513	[Advances in Diagnosis and Treatment of Multiple Primary Lung Cancer]. 2015 , 18, 640-3	2
512	[Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report]. 2015 , 18, 592-8	
511	[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor ?Receptor Mutations in Non-small Cell Lung Cancer]. 2015 , 18, 493-9	4
510	[Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines]. 2015 , 18, 475-80	5
509	[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)]. 2015 , 18, 397-400	1
508	[TKI Resistance for T790M Mutation]. 2015 , 18, 245-50	1
507	[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]. 2015 , 18, 686-90	1
506	[Research progress of targeted therapy in non-small cell lung cancer brain metastases]. 2014 , 17, 824-8	1
505	[Treatment of advanced NSCLC with unknown EGFR gene status?--TKI or chemotherapy?]. 2014 , 17, 709-14	
504	[Advances on driver oncogenes of squamous cell lung cancer]. 2014 , 17, 433-6	
503	[Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes]. 2013 , 16, 25-32	1
502	[Drug induced hepatotoxicity in targeted therapy for lung cancer]. 2014 , 17, 685-8	2
501	[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified]. 2015 , 18, 734-9	5
500	[Clinical Evaluation of A New Pathological Classification for ?Non-small Cell Lung Cancer Based on Histogenesis of Bronchial Tree]. 2018 , 21, 530-535	
499	[Personalized targeted therapy for lung cancer]. 2013 , 16, C21-34	
498	Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. 2018 , 9, 189-200	11
497	Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital. 2019 , 9, 1009-1016	4

496	[Dynamic Changes of Circulating Tumor DNA in Peripheral Blood Predict the Efficacy of TKI in the Treatment of Lung Adenocarcinoma with EGFR Mutation]. 2019 , 22, 568-573	0
495	[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population]. 2019 , 22, 562-567	0
494	EPS8L3 promotes hepatocellular carcinoma proliferation and metastasis by modulating EGFR dimerization and internalization. 2020 , 10, 60-77	4
493	[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer]. 2020 , 23, 274-281	
492	Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with sensitizing mutations. 2020 , 10, 4266-4286	3
491	A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer. 2020 , 13, 3060-3082	2
490	Predicting mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. 2021 , 11, 546-560	6
489	Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. 2021 , 11, 143-153	0
488	[Comprehensive Treatment of An Advanced Lung Cancer Patient with ?EGFR Driver Gene Positive]. 2021 , 24, 447-452	
487	Oligometastatic non-small cell lung cancer: Current management. 2021 , 7, 311-319	0
486	Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. 2021 , 11, 3189-3200	0
485	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	2
484	Recent advances in lung cancer genomics: Application in targeted therapy. 2021 , 108, 201-275	0
483	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. 2021 , 20, 15330338211039676	0
482	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. 2021 , 169, 103561	3
481	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. 2021 , 1877, 188645	4
480	Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies.. 2021 , 8, 761078	1
479	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. 2021 , 13,	1

478	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2021 , 23, 369-402	3
477	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with Mutation-Positive Non-Small Cell Lung Cancer. 2021 , 13, 8695-8705	1
476	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. 2021 , 21, 1247	0
475	Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics. 2021 , 12, 169	1
474	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. 2021 , 89, 105	2
473	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). 2021 , 11, 23140	2
472	The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. 2021 , 13,	3
471	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review. 2021 , 22,	
470	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. 2021 , 1	0
469	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. 2021 , 57,	0
468	Advances in the diagnosis, evaluation, and management of leptomeningeal disease. 2021 , 3, v86-v95	2
467	An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report. 2021 , 100, e27614	0
466	Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. 2021 , 10,	2
465	First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. 2021 ,	0
464	Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. 2021 ,	0
463	Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. 2021 , 13,	2
462	Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. 2021 , 23, 408-417	
461	Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.. 2021 , 10, 4120-4129	1

460	Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.. 2021 ,	0
459	Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. 2021 ,	1
458	Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. 2021 , 6, 100319	4
457	Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.	
456	Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India. 2021 , 5, 104	
455	Encyclopedia of Gerontology and Population Aging. 2021 , 4895-4908	
454	The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.. 2021 , 164, 8-13	0
453	Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.. 2021 , 7, 100347	0
452	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of -Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance.. 2022 , 10,	0
451	Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.. 2022 ,	0
450	A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer.. 2022 , 166, 17-26	3
449	The co-mutation of and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients.. 2022 , 14, 185-193	1
448	Design, Synthesis, Molecular Docking and Biological Studies of New Heterocyclic Compounds Derived from ?-Diketones as Novel EGFR and Pim-1 Inhibitors Endowed with Antitumor Activity.. 2022 ,	0
447	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer.. 2022 , 12,	0
446	The Clinical Efficacy of EGFR-TKIs (Gefitinib or Icotinib) in Adjuvant Therapy for Patients with NSCLC in the Real World. 2022 , 12, 95-103	0
445	Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients.. 2022 , 13, 744-751	0
444	Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome.. 2022 , 31, 100524	0
443	An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety. 2022 , 4, 952-966	1

442	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).. 2022 ,	1
441	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
440	Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.. 2022 , 23, 55	0
439	Molecularly directed therapy of advanced/metastatic non-small cell lung cancer.	
438	Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.. 2022 , 12, e046451	0
437	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations.. 2022 , 12, 766066	0
436	Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.. 2022 , 166, 9-16	1
435	The application of radiomics in predicting gene mutations in cancer.. 2022 , 1	3
434	Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging. 2022 , 9, 44-49	
433	Predicting Anticancer Drug Resistance Mediated by Mutations.. 2022 , 15,	0
432	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.. 2022 , JCO2101626	8
431	Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.. 2022 , 31, 100522	2
430	Computational Methods for the Analysis and Prediction of EGFR-mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.. 2022 , PP,	0
429	Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance.. 2021 , 12, 746707	2
428	Biomarkers in Pulmonary Carcinomas. 2022 , 99-128	0
427	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.. 2022 , 17, 1-13	3
426	Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.. 2022 , 31, 100526	
425	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.. 2022 , 14,	0

424	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.. 2022 , 20, 37-44	0
423	Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).. 2022 , 14,	0
422	Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer.. 2022 , 12, 772770	0
421	Black Phosphorus nanoparticles for dual therapy of non-small cell lung cancer.. 2022 , 1-21	0
420	A Deep Learning solution for triaging patient with cancer from their predicted mutational status using histopathological images.	
419	Effects of Ethnicity on Outcomes of Patients With Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection.. 2022 , 3, 100259	0
418	Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab.. 2022 , 25, 101269	0
417	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.. 2022 , 167, 41-48	0
416	Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma.. 2022 , 12, 793190	1
415	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.. 2022 , 166, 98-106	0
414	Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected -mutated non-small-cell lung cancer: a meta-analysis.. 2022 ,	0
413	Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.. 2022 , 1	1
412	Liquid Biopsy, Diagnostic Imaging, and Future Synergies.. 2022 , 19, 336-343	1
411	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.. 2022 , 12, 843299	0
410	Stability and Formulation of Erlotinib in Skin Creams.. 2022 , 27,	0
409	Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.. 2022 , 12, 2167	1
408	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
407	"How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.. 2021 , 11, 761042	4

406	Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.. 2022 , 16, 30	0
405	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. 2022 , 16, 11795549221080347	0
404	A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.. 2022 , 21, 15330338221078429	0
403	Non-Small Cell Lung Cancer in Older Adults with Frailty. 2022 , 319-339	
402	Neurological complications of lung cancer. 2022 , 243-276	
401	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.. 2022 , 21, 15347354221086663	0
400	Management of Early-Stage Resected Non-Small Cell Lung Cancer: Consensus Statement of the Lung cancer Consortium.. 2022 , 31, 100538	
399	Prognostic factors for treatment response and survival outcomes after first-line management of Stage 4 non-small cell lung cancer: A real-world Indian perspective.. 2022 , 39, 102-109	0
398	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.. 2022 , 14, 17588359221079125	0
397	Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring.. 2022 ,	
396	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI.. 2022 , 14,	0
395	Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.. 2022 ,	0
394	MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.. 2021 ,	5
393	Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug-Protein and Drug-Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches.. 2022 , 27,	9
392	Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.. 2022 , 1	
391	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. 2022 , 21, 61	0
390	Resistance to EGFR inhibitors in lung cancer occurs through horizontal transfer and is associated with increased caveolins expression.	
389	Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.. 2022 , 16, 88	0

388	Challenges in the Use of Targeted Therapies in NSCLC.. 2022,	1
387	Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC.	
386	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.. 2022, 11, 238-249	0
385	The Role of Mutations in -Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.. 2022, 14,	0
384	Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial).. 2022,	0
383	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.. 2022,	2
382	- gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.. 2022, 11, 497-503	
381	Metabolic complete tumor response in a patient with mutant non-small cell lung cancer treated with a reduced dose of afatinib.. 2022, 50, 3000605211058864	1
380	A novel signature based on immune-related gene pairs and clinical features to predict prognosis and treatment effect in "driver gene negative" lung adenocarcinoma.. 2022,	1
379	Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis.. 2022,	1
378	Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERR β -expression.. 2022, 21, 77	3
377	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.. 2022, 14,	0
376	Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for -Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review.. 2022, 15, 3405-3416	0
375	Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.. 2022,	
374	A concise review on tyrosine kinase targeted cancer therapy. 2022, 17,	
373	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.. 2022, 12, 4398	0
372	ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?. 2022, 13, 13-21	0
371	Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.. 2022, 12, 859152	0

370	EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.. 2022 , 167, 78-86	0
369	Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).. 2022 ,	3
368	Hepatic Rupture as the Initial Presentation of an -Mutated Lung Adenocarcinoma: A Case Report.. 2022 , 12, 837630	
367	Aumolertinib: A Review in Non-Small Cell Lung Cancer.. 2022 , 82, 577	1
366	Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.. 2022 , 22, 328	0
365	Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.. 2022 , 1	2
364	EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.. 2022 , 10781552221085253	1
363	Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial.. 2022 , 13, 840889	
362	Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.. 2022 , 3, 100322	0
361	Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.. 2022 , 1	0
360	Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.. 2022 , 7, 100398	0
359	Novel targeted therapies for advanced non-small lung cancer.. 2022 ,	0
358	RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With -Mutated Metastatic NSCLC.. 2022 , 3, 100303	0
357	The Root Extract of Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different Mutation Statuses by Suppressing MET Activity.. 2022 , 27,	
356	Relationship between Biodistribution and Tracer Kinetics of C-Erlotinib, F-Afatinib and C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients.. 2022 , 12,	0
355	Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent E-Catenin Activating FOXO3a Signaling.. 2022 , 12, 855603	
354	Development and validation of novel radiomics-based nomograms for the prediction of mutations and Ki-67 proliferation index in non-small cell lung cancer.. 2022 , 12, 2658-2671	
353	Drug-induced diarrhea associated with antineoplastic drugs. 2021 , 13, 5-18	

352	A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors. 2021 , 26,	3
351	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.. 2021 , 2021, 9311875	3
350	Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.. 2021 , 28, 5179-5191	1
349	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
348	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.. 2021 , 21, 675	1
347	Chronic Stress Effects on Tumor: Pathway and Mechanism.. 2021 , 11, 738252	6
346	Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.. 2021 , 1-14	1
345	MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in -Mutated Non-Small Cell Lung Cancer.. 2021 , 22,	0
344	Lung adenocarcinoma: development of nomograms based on PET/CT images for prediction of epidermal growth factor receptor mutation status and subtypes.. 2021 , 43,	0
343	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.. 2021 ,	2
342	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.. 2021 , 5, 102	2
341	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	5
340	Exceptional response to afatinib in a patient with persistent G719A -mutant NSCLC.. 2022 , 11, LMT54	0
339	The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.. 2022 , 29, 2630-2643	0
338	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.. 2022 , 12, 6367	1
337	Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their role in the Treatment of Cancer: A Review.. 2022 ,	1
336	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.. 2022 , 82, 649	2
335	Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).. 2022 ,	

334	EGFR signaling pathway as therapeutic target in human cancers.. 2022,	1
333	Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).. 2022, 168, 38-45	0
332	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.. 2022, OF1-OF18	4
331	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer.. 2022, 12, 870636	1
330	Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.. 2022, 23,	0
329	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.. 2022,	7
328	Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations.. 2022,	1
327	FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer.. 2022, 45, 293	0
326	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.. 2022, 168, 10-20	0
325	Data_Sheet_1.PDF. 2019,	
324	Image_1.JPEG. 2020,	
323	Image_2.JPEG. 2020,	
322	Table_1.DOCX. 2020,	
321	Image_1.PDF. 2020,	
320	Table_1.XLSX. 2020,	
319	Table_2.XLSX. 2020,	
318	Table_1.docx. 2020,	
317	Table_2.docx. 2020,	

316 Table_3.docx. **2020**,

315 Table_1.DOCX. **2020**,

314 Data_Sheet_1.pdf. **2020**,

313 Table_1.docx. **2020**,

312 Table_2.docx. **2020**,

311 Table_1.pdf. **2020**,

310 Table_2.pdf. **2020**,

309 Table_1.docx. **2020**,

308 Image_1.JPEG. **2019**,

307 Image_2.jpg. **2019**,

306 Image_3.jpeg. **2019**,

305 Image_4.jpeg. **2019**,

304 Image_1.tif. **2021**,

303 Table_1.docx. **2021**,

302 Table_1.docx. **2020**,

301 Table_2.docx. **2020**,

300 DataSheet_1.docx. **2021**,

299 Image_1.tiff. **2021**,

298 Image_2.tiff. **2021,**

297 Image_3.tiff. **2021,**

296 DataSheet_1.docx. **2019,**

295 DataSheet_2.docx. **2019,**

294 DataSheet_3.doc. **2019,**

293 DataSheet_4.docx. **2019,**

292 Image_1.tif. **2019,**

291 The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.. **2022,** 1

290 Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.. **2022,** 0

289 An extraction from *Trametes robiniophila* Murr. () inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor.. **2022,** 13, 10931-10943

288 [Pattern of Recurrence and Metastasis after Radical Resection of ?Non-small Cell Lung Cancer].. **2022,** 25, 26-33

287 Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as âROS1âs it appears?. **2017,** 34, 405 2

286 Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.. **2022,** 12, 7002 0

285 Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series.. **2022,** 13, 912153 0

284 Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. **2022,** 14, 1

283 Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. **2022,** 20, 497-530 24

282 Association between epidermal growth factor receptor gene mutation status and short-term efficacy of first-line platinum-containing chemotherapy in advanced non-small cell lung cancer. **2022,** 17, 0

281 Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy.. **2022,** 11, 24 0

280	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. 2022 , 22, 514	1
279	A comparison of methods for enriching network meta-analyses in the absence of individual patient data.. 2022 ,	
278	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.. 2022 ,	
277	Extracellular PKC β signals to EGF receptor for tumor proliferation in liver cancer cells.. 2022 ,	1
276	The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.. 2022 , 22, 491	0
275	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. 2022 ,	2
274	Sex and gender differences in anticancer treatment toxicity - a call for revisiting drug dosing in oncology.. 2022 ,	1
273	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor- β s predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. 2022 , 100576	
272	Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. 2022 , 13,	
271	Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping.. 2022 ,	0
270	Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.. 2022 , 7, 100473	
269	Safety and efficacy of epitinib for EGFR-mutant non-small cell lung cancer with brain metastases: open-label multicentre dose-expansion phase Ib study. 2022 ,	
268	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. 2022 , 14,	0
267	Lung Cancer. 2022 , 259-283	
266	Pleural, Pericardial, and Peritoneal Fluids. 2014 , 127-153	2
265	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.. 2022 ,	0
264	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.. 2022 , 20, 159	1
263	Machine learning-based algorithm demonstrates differences in del19 and L858R EGFR subgroups in non-small cell lung cancer: a single center experience.. 2022 , 14, 2677-2684	

262	The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer.	
261	Percutaneous Image-guided Biopsy for a Comprehensive Hybridization Capture-based Next-generation Sequencing in Primary Lung Cancer: Safety, Efficacy, and Predictors of Outcome. 2022 , 100342	
260	APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling. 2022 , 12,	1
259	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. 2022 , 14, 2613	0
258	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. 2022 , 14, 2519	1
257	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. 2022 , 12,	0
256	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent &i>EGFR&/i>; T790M Mutated NSCLC: A Phase IIb Study.	
255	Improving the tolerability of osimertinib by identifying its toxic limit. 2022 , 14, 175883592211032	1
254	HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. 2022 ,	0
253	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. 2022 , 14, 2744	1
252	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.	0
251	Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.	
250	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. 2022 , 22,	
249	Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. 2022 ,	5
248	Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario. 2022 , 10,	
247	AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. 2022 , 12,	0
246	Estimating the replicability of highly cited clinical research (2004-2018).	
245	When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan. 2022 , 22,	0

244	Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer.	0
243	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. 2022 , 11,	0
242	An integrated biomarker of PD-L1 expression and intraepithelial CD8 + T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.	0
241	Perioperative targeted therapy for oncogene-driven NSCLC. 2022 ,	1
240	The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases. 2022 , 26, 290-297	0
239	Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression. Volume 14, 1891-1902	
238	Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1. 2022 , 13,	0
237	Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. 1-20	
236	Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.	
235	Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study. 2022 ,	0
234	Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. 2022 , 65, 8416-8443	2
233	Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. 12,	0
232	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. 2022 , 12,	1
231	Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. 2022 , 11, 3366	1
230	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. 13,	0
229	Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. 2022 , 23, 6936	2
228	A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancer.	
227	Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.	1

- 226 Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. ○
- 225 Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. **2022**, 13, 897
- 224 Hematological Toxicity in Lung Cancer. **2022**,
- 223 Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting. 12,
- 222 Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. ○
- 221 Cost-effectiveness of osimertinib versus placebo in resected EGFR -mutated non-small cell lung cancer in China.
- 220 Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. 12, ○
- 219 Clinical Experience on Use of Oral EGFR-TKIs as First-line Treatment of Advanced NSCLC from a Tertiary Care Centre in North India and Implications of Skin Rash. **2022**, 56, 149-152
- 218 Integrin β Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway. **2022**, 11, 2078 1
- 217 Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. **2022**, 63, 700-708 ○
- 216 Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study.
- 215 Treating advanced lung cancer in older veterans with comorbid conditions and frailty. **2022**,
- 214 Clinically-meaningful improvements in therapy for unresectable NSCLC. ○
- 213 Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
- 212 "Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients. 12, ○
- 211 The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer. **2022**, 13,
- 210 Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Is NF1 Tumor Suppressor a Key Role in Acquired Resistance?. **2022**, 14, 3323
- 209 Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. **2022**, 240, 114602 ○

- 208 Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report.
- 207 Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13, 0
- 206 The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients. **2022**, 1-7
- 205 Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. 12, 0
- 204 Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis. **2022**, 177, 103760 1
- 203 Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. 2
- 202 Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. **2022**, 12, 1799 2
- 201 Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. **2022**, 23, 8541 0
- 200 Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. **2022**, 1-11
- 199 Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC Patients. **2022**,
- 198 18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer. **2022**, 0
- 197 PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. 12, 1
- 196 Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition. 1
- 195 The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2022**, 29, 6137-6153 2
- 194 Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
- 193 The nomogram for the prediction of overall survival in patients with metastatic lung adenocarcinoma undergoing primary site surgery: A retrospective population-based study. 12, 1
- 192 Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. 0
- 191 Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. **2022**, 13, 1499

190	Perioperative Systemic Therapy for Resectable Non-small Cell Lung Cancer. 2022 , 20, 953-961	1
189	Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.	
188	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.	
187	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
186	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.	0
185	The Ethanolic Extract of <i>Trichosanthes Kirilowii</i> Root Exerts anti-Cancer Effects in Human Non-Small Cell Lung Cancer Cells Resistant to EGFR TKI. 1-12	
184	Label-free visualization of cellular response to molecularly targeted agents using multiplex CARS and THG (coherent anti-Stokes Raman scattering and third harmonic generation) microscopy.	
183	Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study. 2022 ,	0
182	Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. 2022 , 37, 2265-2282	2
181	P21-activated kinase 2-mediated Eatenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.	1
180	An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. 12,	1
179	Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. 2022 , 12,	0
178	Drug resistance in NSCLC is associated with tumor micro-environment. 2022 , 22, 100680	0
177	Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. 2022 , 172, 86-93	0
176	Some 2-(4-bromophenoxymethyl)-6-iodo-3-substituted quinazolin-4(3H)ones: Synthesis, cytotoxic activity, EGFR inhibition and molecular docking. 2022 , 1269, 133851	
175	Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. 2022 , 14, 175883592211132	0
174	Translational Research in Lung Cancer. 2022 ,	0
173	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,	1

- 172 Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. ○
- 171 Genomic Alterations in Lung Cancer. **2022**, ○
- 170 Device Trials. **2022**, 1399-1416 ○
- 169 Personalized prediction of response to smartphone-delivered meditation training: A machine learning approach (Preprint). ○
- 168 cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small-cell lung cancer via ERK pathway. **2022**, ○
- 167 High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. **2022**, 10, 2109 ○
- 166 A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). **2022**, ○
- 165 Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors. **2022**, 70, 637-641 ○
- 164 The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI Therapy. ○
- 163 Endobronchial Ultrasound-guided Sampling of Centrally Located Intrapulmonary Tumors Provides Suitable Material for Diagnostic and Molecular Testing. Publish Ahead of Print, 1
- 162 EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. ○
- 161 Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs. ○
- 160 Minimal residual disease in EGFR-mutant non-small-cell lung cancer. 12, ○
- 159 Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. **2022**, 31, 1647-1662 ○
- 158 Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. 12, ○
- 157 Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy. ○
- 156 Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature. ○
- 155 NCPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. **2022**, 14, 4395 ○

154	Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis. 2022 , 24,	0
153	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. 2022 , 14, 4759	0
152	Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. 2022 , 23, 11353	0
151	Germline Mutations in High Penetrance Genes are Associated with Worse Clinical Outcomes in Patients with Non-Small Cell Lung Cancer. 2022 ,	0
150	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. 2022 , 7,	0
149	Clinicopathologic Characteristics and Prognostic Impact of Atypical EGFR Mutations in Completely Resected Lung Adenocarcinoma. 2022 ,	1
148	Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. 2022 , 106188	1
147	Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer. 12,	0
146	Generation of genetically engineered mice for lung cancer with mutant EGFR. 2022 , 632, 85-91	0
145	First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. 2022 , 13, 204062232211257	0
144	Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations. 2022 , 16, 175346662211327	0
143	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. 2022 , 251-267	0
142	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. 2022 ,	0
141	Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.	0
140	Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. 1-7	0
139	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. 2022 , 23, 1626-1644	1
138	Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de lâEGR. 2022 , 14, 25189-25208	0
137	Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)â Single Center, Retrospective Observational Study. 2022 , 23, 12511	0

- 136 Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. ○
- 135 Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives. **2022**, 14, 4954 ○
- 134 TAS2940 , a Novel Brain-Penetrable Pan-ERBB Inhibitor, for Tumors with HER2 and EGFR Aberrations. ○
- 133 Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. **2022**, 14, 5095 1
- 132 State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV. ○
- 131 The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. **2022**, 17, e0275919 ○
- 130 Landscape of the clinical development of China innovative anti-lung cancer drugs. **2022**, ○
- 129 Precision Medicine in Oncology Drug Development. 1-15 ○
- 128 Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-9 ○
- 127 Small molecule inhibitors targeting the cancers. **2022**, 3, ○
- 126 Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. **2022**, 14, 4861 ○
- 125 Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients –an overview. 12, ○
- 124 Cancer of the Lung. 1-29 ○
- 123 Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. **2022**, 14, 5119 ○
- 122 Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l'EGFR. **2022**, ○
- 121 A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells. **2022**, 636, 125-131 1
- 120 Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience. **2022**, 16, 175346662211353 ○
- 119 Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib. **2022**, 11, 5-9 ○

118	Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru.	0
117	Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung.	0
116	The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with tyrosine kinase inhibitors.	0
115	Regression of Lung Cancer in Mice by Intranasal Administration of SARS-CoV-2 Spike S1. 2022 , 14, 5648	3
114	Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study.	0
113	RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report. 12 ,	0
112	Clinical outcomes of EGFR-mutated NSCLC patients with leptomeningeal metastasis in the modern target therapy era. 2022 ,	0
111	A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. 2022 , 13,	0
110	Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer. 2022 , 108445	0
109	A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. 2022 , 174, 133-140	0
108	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. 2022 , 153-172	0
107	Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study. 2022 , 21, 153303382211382	0
106	The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada. 2023 , 175, 60-67	0
105	Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. 2023 , 8, 100741	1
104	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. 2022 , 14, 175883592211440	0
103	ASTRIS, estudio de mundo real con osimertinib en pacientes EGFR mutados, progresados con T790M. 2018 , 23,	0
102	The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis. 2022 , 24, 340-344	0
101	A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.	0

- 100 Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. ○
- 99 Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. **2022**, 24, 269-304 ○
- 98 CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. ○
- 97 Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). ○
- 96 ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion. 2, ○
- 95 Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. **2022**, 10, 3008 ○
- 94 PROTAC therapy as a new targeted therapy for lung cancer. **2022**, ○
- 93 Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. **2022**, 13, 2183 ○
- 92 Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study. **2022**, ○
- 91 Assessment of Tissue Adequacy by EBUS in Conjunction with PET Scan and Operator's Experience. **2022**, 12, 942-949 ○
- 90 Thieno[2,3-b]thiophene Derivatives as Potential EGFRWT and EGFR T790M Inhibitors with Antioxidant Activities: Microwave-Assisted Synthesis and Quantitative In Vitro and In Silico Studies. **2022**, 7, 45535-45544 2
- 89 Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. **2022**, 1-12 ○
- 88 Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. Volume 14, 3421-3435 ○
- 87 Simultaneously evaluating efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor. ○
- 86 Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials. **2022**, 101, e32164 ○
- 85 Clinical case of long-term disease control in a patient with <i>EGFR</i>-positive non-small cell lung cancer. **2022**, 154-159 ○
- 84 Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease. ○
- 83 Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor. **2022**, 23, 15828 ○

82	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. 2022 , 15,	1
81	TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. 2022 , 14, 6127	0
80	Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. 2022 , 23, 15056	1
79	Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. 2023 , 30, 145-156	0
78	Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. 2023 , 15, 504	1
77	Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. 2023 , 133,	0
76	Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer. 12,	0
75	A clinically validated human saliva metatranscriptomic test for global systems biology studies.	0
74	EGFR-Directed Therapy in Lung Cancer. 2023 ,	0
73	Importancia del test de mutaci3n del receptor del factor de crecimiento epid3mico en c3ncer de pulm3n de c3lulas no pequeas. 2015 , 20,	0
72	Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study. 2023 , 12, 236	0
71	Targeting KRAS G12C mutations in colorectal cancer. 2022 , 11,	0
70	The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. 2022 , 12,	0
69	The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer. 2023 , 13, 129	0
68	Major pathologic response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.	0
67	A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer. 2023 , 23,	1
66	FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. 29,	0
65	Gender is a non-negligible risk factor affecting the overall survival time of NSCLC patients: a nationwide population-based study.	0

- 64 Apoptosis signaling in EGFR inhibitor resistance in NSCLC. **2023**, 71-88 ○
- 63 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 62 Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection â systematic review. **2023**, ○
- 61 Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. **2023**, 15, 642 ○
- 60 Upfront and repeated stereotactic radiosurgery in patients with brain metastases from NSCLC. **2023**, ○
- 59 Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. **2023**, 15, 175883592211461 ○
- 58 Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. **2023**, ○
- 57 Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study. **2023**, 15, 175883592311614 ○
- 56 Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. **2023**, 185, 83-93 ○
- 55 Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. **2023**, 669, 115115 ○
- 54 Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects. **2023**, 88, 100964 ○
- 53 NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature. **2023**, 10, 100232 ○
- 52 Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. ○
- 51 Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer. **2022**, 24, 613-648 ○
- 50 Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. **2023**, 15, 629 ○
- 49 Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant NonâSmall Cell Lung Cancer. **2023**, 13, 210 ○
- 48 The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center. 13, ○
- 47 Endobronchial ultrasound bronchoscopy Franseen fine needle biopsy tool versus standard fine needle aspiration needle: Impact on diagnosis and tissue adequacy. **2023**, 208, 107131 ○

- 46 Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. **2023**, 178, 28-36 ○
- 45 Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report. **2023**, 34, 455-459 ○
- 44 Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. **2023**, 4, 100468 ○
- 43 Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. **2023**, 11, 448 ○
- 42 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 41 Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2. **2023**, 81, 117202 ○
- 40 CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. **2023**, 41, 340-355.e6 ○
- 39 Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials. **2023**, 21, ○
- 38 Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. **2023**, 19, 147-158 ○
- 37 Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. **2023**, 102, e32697 ○
- 36 Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. **2023**, 24, 4126 ○
- 35 Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. **2023**, 23, 1
- 34 Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. **2023**, 23, ○
- 33 Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. **2023**, 18, 195-207 ○
- 32 Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. **2023**, 21, ○
- 31 Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. ○
- 30 Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III&IV lung adenocarcinoma. **2023**, 22, 5-14 ○
- 29 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 ○

- 28 The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer. **2023**, 24, 4827 ○
- 27 Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. **2023**, 8, 101160 ○
- 26 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 25 Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?. **2023**, 62, 298-304 ○
- 24 Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. **2023**, 23, ○
- 23 Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study. 13, ○
- 22 Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study. **2023**, ○
- 21 UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K / AKT / mTOR signaling pathway. ○
- 20 NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. **2023**, 13, 1117 ○
- 19 Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016-2020: a retrospective observational study based on inpatient and outpatient hospital data. **2023**, 13, e069645 ○
- 18 Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review. **2023**, 24, 5858 ○
- 17 Therapeutic potential of TRPM8 channels in cancer treatment. 14, ○
- 16 Research Progress on the Anti-Tumor Mechanism and Reversal of Multidrug Resistance of Zuojin Pill and its Main Components, Evodiamine and Berberine. **2023**, 18, 1934578X2311614 ○
- 15 Prolonged response to first-generation tyrosine kinase inhibitor in a metastatic non-small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review. **2023**, 11, ○
- 14 Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan. **2023**, 13, ○
- 13 Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study. **2023**, 23, ○
- 12 Ultra-rapid Idylla-EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer. 13, ○
- 11 The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. **2023**, ○

- 10 Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review. ○
- 9 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○
- 8 The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. **2023**, 2023, 1-8 ○
- 7 Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs. Volume 15, 351-362 ○
- 6 Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. 13, ○
- 5 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 4 Personalized treatment for patients with lung cancer. ○
- 3 Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults. **2023**, 23, ○
- 2 First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. **2023**, 15, 2382 ○
- 1 Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country. **2023**, 30, 107327482311752 ○